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ENGINEERING AND EVOLVING HELICAL PROTEINS THAT IMPROVE IN VIVO  




Methods for the stabilization of well-defined helical peptide drugs and basic research 
tools have received considerable attention in the last decade. Enfuvirtide is a 36-residue 
chemically synthesized helical peptide that targets the viral gp41 protein and inhibits viral 
membrane fusion. Enfuvirtide-resistant HIV, however, has been prolific, and this peptide therapy 
requires daily injection due to proteolytic degradation.  
In this dissertation I have developed a method for stabilizing helical peptide therapeutics 
termed helix-grafted display proteins. These consist of the HIV-1 gp41 C-peptide helix grafted 
onto Pleckstrin Homology domains. Some of these earlier protein biologics inhibit HIV-1 entry 
with modest and variable potencies (IC50 190 nM - >1 μM). After optimization of the scaffold 
and the helix, our designer peptide therapeutic potently inhibited HIV-1 entry in a live-virus 
assay (IC50 1.9-12.4 nM). Sequence optimization of solvent-exposed helical residues using yeast 
display as a screening method led to improved biologics with enhanced protein expression in 
Escherichia coli (E. coli, a common bio-expression host), with no appreciable change in viral 
membrane fusion suppression. Optimized proteins suppress the viral entry of a clinically-relevant 
double mutant of HIV-1 that is gp41 C-peptide sensitive and Enfuvirtide-resistant. Protein 
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Protein Engineering and Evolution Approaches to Evaluate and 





The α-helix is the most prominent secondary structure in protein folds.[1] This common 
motif is found in protein-protein interactions (PPIs) involved in virtually all aspects of cellular 
function and signaling.[2] Due to the ubiquitous nature of this secondary structure, it has been of 
immense importance and focus for scientific research for the last century and probing or inhibiting 
these helical interactions has a high pharmacological relevance.[3, 4]  
Diseased states involving a helical ligand encompass a variety of cancer receptors, either 
intracellular or extracellular, as well as viral membrane fusion of some of the most lethal viruses 
plaguing humanity. Human epidermal growth factor receptor 2 (HER2) is an extracellular target 
overexpressed on breast cancer cells which has become a target of particular interest in the cancer 
community.[5] The tumor suppressor p53 has been found to contain alterations in a large majority 
of cancers preventing functional activation which signals for apoptosis of cancer cells. Turning on 
this pathway could be a potential route for eradicating cancer cells.[6-8] HIV, Lassa Virus, Ebola 
virus all contain viral envelope proteins which fold into a 6-helix bundle, promoting membrane 
fusion and cell entry of the viral cargo. Inhibition of membrane fusion not only inhibits viral entry, 
but can prevent latent reservoirs of retroviruses from forming.[9-11] This review will highlight the 





1.2 Bacterial Expression of Peptides 
The perhaps most obvious solution to probing and inhibiting protein-protein interactions 
involving an α-helix is to mimic the helical ligand involved in the PPI with a peptide.[2, 12] While 
peptides can be manufactured through synthetic routes using solid-phase peptide synthesis, many 
efforts have been advanced to effectively express and purify a peptide in Escherichia coli (E. 
coli).[13, 14] This significantly lowers the cost of production and improves the yield, especially in 
the case of extended helical peptides (greater than 20 amino acids). Expressing a peptide by itself 
in E. coli can be problematic because many peptides lack solubility in a sequence-dependent 
manner and, in the absence of a stabilizing tertiary structure, are unstable and partially unfolded in 
solution making them particularly susceptible to peptidases and proteolytic degradation. 
Recombinant protein fusion approaches overcome the stability and solubility challenges, allowing 
for protein expression in a bacterial system and cost-effective purification of the peptide.[14]  
Successful recombinant protein fusions bestow enhanced stability, and often solubility to 
the peptide. The fusion protein itself must exhibit hyperstability and high expression in the E. coli 
host to overcome the tendency for the insoluble peptide-of-interest to aggregate in inclusion 
bodies. The fusion must also contain an affinity tag for purification and a sequence-specific method 
for cleaving the protein fusion post-purification to separate the peptide (Figure 1.2A).[13-16] 
Proteins such as NusA and thioredoxin (TRX) exhibit the solubility properties necessary for 
peptide expression but must include a separate affinity tag fusion for purification and a protease 
cleavage site (Figure 1.2B).[17-19] Small ubiquitin-like modifier (SUMO), and ubiquitin (Ub) 
contain a site-specific recognition for enzymatic cleavage of the protein fusion from the peptide-
of-interest, but still require an affinity tag for purification (Figure 1.2C).[20-24] Glutathione S-
transferase (GST), maltose binding protein (MBP) and protein-A function as fusion proteins and 
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affinity tags, but still require a protease cleavage site to separate the peptide from the fusion post-
purification (Figure 1.2D).[15, 25-28]  
In a somewhat unique approach, a new emerging class of fusion proteins sequesters the 
protein products in inclusion bodies. This protects the peptides from proteolytic degradation and 
allows for easy separation through centrifugation of cell lysates. However, many of these fusions, 
including bacterial ketosteroid isomerase (KSI), the autoprotease Npro of classical swine fever 
virus and the elastin-like polypeptide (ELP), require chemical cleavage of the fusion from the 
peptide and often involve a refolding procedure for a functional peptide (Figure 1.2E).[29-31] In 
a recent study, Zhao et. al. combined the self-assembling peptide, ELK16, with a self-cleavable 
Mxe GyrA intein tag to produce a fusion that protects the peptide-of-interest in inclusion bodies 
during expression and centrifugal separation and induces cleavage of the fusion in the presence of 
dithiothreitol (DTT). If the peptide is soluble, the pure product will be released to the soluble 
fraction post-cleavage.[32] 
 Whether produced through chemical synthesis or bacterial expression, peptides resemble 
the native binding interaction and can be used to probe PPIs or inhibit their interactions. However, 
peptides are not considered ideal candidates for therapeutic design. In solution, they are unstable 
and partially unfolded leaving an entropic cost associated with binding and are once again 
susceptible to proteolytic degradation and rapid recycling in vivo. Counteracting these drawbacks 






Figure 1.2 (A) Peptide expression schematic. Properties necessary for expressing a functional 
peptide (blue) using protein fusions requires: highly stable fusion protein to keep peptide in the 
soluble lysate (lavender), an affinity tag for purification (grey), and a protease cleavage site for 
peptide isolation (black).  (B) Fusion proteins NusA and TRX which require an affinity tag and 
a protease cleavage site (PDB: 5LM9 and 1T00). (C) Fusion proteins SUMO and Ub which 
only require an affinity tag as the proteins act as a self-cleavable fusion (PDB: 1WM3 and 
4MDK). (D) Protein fusions GST, MBP, and Protein-A which only require a protease cleavage 
site as the fusion protein acts as an affinity tag (PDB: 5LCZ, 1NMU and 4WWI). (E) Fusion 
proteins Npro and KSI which function by protecting peptide in insoluble fraction and can be 
isolated from the cell inclusion bodies with chemical cleavage (PDB: 3ZFN and 3VSY).  
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1.3 Chemical Approaches to Helical Stabilization 
Small molecules have been an attractive solution for developing drug leads over the last 
century. Typically, small molecule approaches to targeting protein-protein interactions have been 
to mimic substrates or transition state analogues that fit within a well-defined hydrophobic pocket 
(Figure 1.3A).[33] Protein-protein interactions that involve a helical ligand generally do not fit 
within this canonical small molecule model and are challenging to target due to the large surface 
area involved in the binding interface. Researchers have come up with alternative chemical 
approaches to disrupt protein-protein interactions involving an α-helix through the synthesis of 
peptide mimetics; either functional mimetics that do not resemble a helical structure but still bind 
the identical interface or helical mimetics that functionally and structurally resemble a helical 
peptide.[34]  
There have been some advancements of functional mimetics that bind the chemical space 
occupied by a specific α-helix, although this strategy has yielded few developments towards a 
general approach to target helical binding pockets. Hoffmann–La Roche, Shaomeng Wang group 
and Johnson and Johnson Pharmaceuticals generated small molecule drugs that inhibit the 
p53/MDM2 interaction. These inhibitors were found using high-throughput screening or virtual 
screening and include tetra-substituted imidazoles (Nutlins), spirooxindoles and 
benzodiazepinediones (Figure 1.3B).[35-37] 
Helical mimetics that both functionally and physically resemble a peptide have shown vast 
improvements in disrupting disease-relevant PPIs as well as general engineering strategies for 
targeting helical interfaces. Constrained peptides, foldamers and proteomimetic-derived ligands 
bind to the helical interface and can improve stability compared to peptides, prevent proteolytic 
degradation, and target a larger surface area than the typical small molecule drugs.[38] Constrained 
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peptides comprise of a number of different motifs including cyclic peptides at their simplest form 
to bicyclic peptides and stapled peptides. Biophysical and Analytical Technologies at Aileron 
developed a stapled peptide that also targeted the p53/MDM2 PPI. The phase II drug candidate, 
ALRN-6924, binds to both MDM2 and MDMX by resembling the helical interface of p53 and is 
stabilized by hydrocarbon linkers (Figure 1.3C).[39] Foldamers are a chemically synthesized 
molecules that mimics the folded conformation of a biological macromolecule, but do not contain 
the typical linkages found in the natural molecule.[40, 41] This biologically orthogonal structure 
allows helical foldamers to evade peptidases or proteases in solution, thus overcoming the basic 
challenges of peptide therapies. Mixed α/β-peptides are a commonly used foldamer to resemble 
the helical motif. The Gellman group utilized this strategy to disrupt the PPI necessary for HIV-1 
membrane fusion (gp41 6-helix bundle formation) by synthesizing an α/β-peptide that resembles 
the Cpeptide binding interface of gp41 (Figure 1.3D).[42, 43] Proteomimetics are a simplified 
helical interface mimetic that works by occupying the identical R group position of an α-helix 
without mimicking the entire helical structure. Hamilton et al. synthesized a 3,2’,2’-functionalised 
terphenyl derivative to mimic the Cpeptide binding face of gp41 to inhibit HIV-1 membrane 
fusion.[44]  
While these chemical methods for helical mimicking and stabilization have been successful 
as therapeutic designs over the last 15 to 20 years, they have significant drawbacks from a 
production and pharmacokinetic standpoint. Chemical synthesis is not only a tedious and costly 
method for therapeutic production, as the yield generally decreases with increasing molecular size, 
but because these synthetic routes produce smaller molecules (< 30 kDa) they are excreted through 





1.4 Protein Grafting for Helical Stabilization 
 An alternative helix stabilization method utilizes protein engineering to solubilize and 
stabilize a peptide mimic on a well-understood tertiary fold.[46] The design starts with a protein 
scaffold that contains a solvent-exposed α-helix. Based on the overall architecture of the scaffold 
protein, the peptide mimic could range from a small coiled-coil motif to a larger helical bundle 
consisting of three to four stabilizing helical assemblies.[47, 48] Some protein scaffolds contain a 
mixture of α-helices and beta sheets arranged in such a way that the solvent-exposed helical ligand 
Figure 1.3 (A) Canonical small molecule in a well-defined hydrophobic binding pocket. 
(Example of human Src kinase bound to kinase inhibitor bosutinib, PDB: 4MXO) (B) Crystal 
structure of Nutlin-2 and MDM2 complex. Representation of a functional helix mimetic which 
occupies a helical binding site (PDB: 1RV1). (C) Crystal structure of the stapled p53 peptide 
bound to MDM2. Representation of a helical mimic stabilized by a hydrocarbon linker (PDB: 
3V3B). (D) Crystal structure of a chimeric α + α/β-peptide analogue of the Cpeptide domain of 
gp41 in complex with the Npeptides of gp41. Representation of a helical mimetic stabilized by 
a foldamer backbone arrangement (PDB: 3G7A).  
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is cradled by the tertiary arrangement, thus enhancing the helical stability and promoting helical 
propensity.[49, 50] The benefit to this strategy is that the peptide mimic is easily expressible in E. 
coli (a common bioproduction host), is more resistant to proteolytic degradation and, depending 
on size, can improve pharmacokinetics in vivo compared to a peptide, peptide mimetic or small 
molecule.[45]  
 The Kim lab and Schepartz lab paved the way for protein grafts in developing unique 
techniques to display binding interfaces on small tertiary structures. This endows greater stability 
of peptides and resistance to proteolytic degradation. Schepartz lab designed ‘miniature proteins’ 
with a solvent-exposed α-helix supported by a single beta strand (Figure 1.4A).[49, 51] In grafting 
on a disease-relevant helical peptide, these structurally sound proteins can specifically target and 
inhibit disease-relevant PPIs. One such miniature protein, p007, utilized the helical binding 
interface of GCN4 grafted onto a small but stable avian pancreatic polypeptide (aPP) to generate 
a grafted protein with nanomolar binding affinity for DNA recognized by GCN4.[49] Kim et al. 
generated peptide dimers in a coiled-coil arrangement to utilize as a scaffold protein structure on 
which to graft the disease-relevant peptide (Figure 1.4B).[47] These dimers include solvent-
exposed hydrophilic residues which increase solubility of the protein. The dimeric complex allows 
for greater stability of the protein. In one such study, Kim and colleagues grafted gp41 Cpeptide 
onto this coiled-coil to generate an antiviral inhibitor for HIV-1 membrane fusion. While these 
studies set the protein grafting technique in motion, they both utilize peptide synthesis to produce 
the therapeutics, thus limiting the cost-effective nature of the design.[47]  
 More recently affibodies emerged as a useful structural motif for engineering stabilized 
helical grafts. Affibodies are small, single domain proteins (58 amino acids, ~6 kDa) arising from 
the B-domain of Protein A and consisting of a three-helix bundle (Figure 1.4C).[48, 52] They have 
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been designed to maintain structural integrity in harsh environments and their small size has made 
them useful as imaging tools with chemical conjugation. Feldwisch et al. optimized affinity 
proteins using an affibody as a molecular scaffold. They adapted the solvent exposed residues on 
one helical ligand to resemble the peptide ZHER2:342 which binds the human epidermal growth factor 
receptor 2 (HER2) involved in many cancers, including breast cancer.[53] While these scaffolds 
have proven enormously useful in generating high affinity and specificity in protein therapeutics, 
they are limited by the length of the peptide binding interface.  
 In another approach, our lab used Pleckstrin Homology (PH) domains as the foundation 
for the helical graft. PH domains have a solvent-exposed C-terminal α-helix cradled by tertiary 
beta sheets which allow it to be useful in grafting on important helical residues on the existing 
helix as well as extending the helix to cover a range of helical binding interfaces (Figure 1.4D).[50] 
In this protein engineering strategy, termed ‘helix-grafted display’ we focused on designing 
Cpeptide mimics that binds to and inhibits the gp41 membrane fusion protein in HIV-1 with an 
IC50 comparable to the FDA approved peptide inhibitor Enfuvirtide, but with improved in vivo 
stability.[54, 55]  
 Helix-grafting has proven to be a highly functional and cost-effective method for helix-
stabilization. The peptide mimics generally show improved resistance to proteolytic degradation 
and similar binding affinities to the original peptide. Enhancing the binding profiles for these 





1.5 Evolving Helical Proteins  
 Grafting existing ligands onto a protein is a good starting point in engineering novel PPIs 
or inhibitors, but the binding affinities for some of these interactions have room for improvement, 
as nature doesn’t always select for the tightest affinities in a dynamic system. Evolving helical 
proteins for improved recognition of a PPI has been a major focus of recent research in probing 
and developing potential therapeutics. Selection and screening methods for proteins/helical ligands 
have varied and include tools like phage display, ribosome display, bacterial display, yeast display, 
yeast two-hybrid, and many others are still being developed. This review will cover some of the 
screening methods used to generate more potent helical grafts.  
Figure 1.4 (A) Helix-grafting onto a miniature aPP protein. Density blue spheres indicate sites 
that have been mutated on the original scaffold (PDB: 2BF9). (B) Helix-grafting onto a coiled-
coil leucine zipper motif. Density blue spheres indicate sites that have been mutated on the 
original scaffold (PDB: 4DMD). (C) Helix-grafting onto an affibody protein-A. Density blue 
spheres indicate sites that have been mutated on the original scaffold (PDB: 1Q2N). (D) Helix-
grafting onto a PH-like Domain, Sac7d. Density blue spheres indicate sites that have been 
mutated on the original scaffold and density blue ribbon represents helical extension from the 
native helix (PDB: 2XIW and 1AIK). 
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 Phage display is still the most widely utilized method for screening a diverse protein library 
(Figure 1.5A).[56] The protein library is genetically fused to a phage coat protein and is therefore 
displayed on the surface of the assembled phage. The protein library can be screened for binding 
to a particular protein of interest by biopanning in vitro and amplifying enriched clones in E. 
coli.[56] In affibody design, phage display libraries were created and selected for by biopanning 
against a specific target or receptor.[46, 48, 53] This research has generated affibodies with 
affinities ranging from picomolar to micromolar binding interactions against targets such as 
insulin, serum albumin, HER2 receptor, just to name a few. The highest affinity-matured affibody 
protein to date is one that targets the Erb2 domain of HER2 with a KD of 22 pM from Orlova et 
al.[53]  
 Ribosome display and bacterial display are less common but highly effective methods for 
improving binding profiles for helical proteins. Ribosome display allows the RNA encoding a 
specific library member to be tethered to the functional protein in which it encodes by stopping 
the translational process on a ribosome and screening for high affinity binders in vitro. The 
enriched clones can be reverse-transcribed and the DNA library amplified by a PCR reaction 
(Figure 1.5B).[57] Bacterial display utilizes the proteins on E. coli that are transported and exposed 
to the extracellular space. The protein library is genetically fused to this membrane protein and 
displayed on the outside of E. coli. Screening for high affinity binders to a specific protein of 
interest can be done using Fluorescence Activated Cell Sorting (FACS) (Figure 1.5C).[58, 59] 
Ankyrin repeat domains are a challenging scaffold to diversify with their repetitive nature. N- and 
C-terminal capping repeats were designed in work by Binz et al. to avoid aggregation, and these 
protein libraries were displayed and selected for in E. coli using ribosome display.[60] This yielded 
two kinase inhibitors (JNK2 and p38) with improved affinity in the nanomolar range.   
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 Yeast display developed by the Wittrup lab has become an emerging tool for screening 
diverse protein libraries, as it utilizes a eukaryotic host with chaperones to improve not only 
affinity, but also to enrich for protein stability and expression (Figure 1.5D).[61, 62] In yeast 
display, much like bacterial display, the protein library is genetically fused to a membrane-
associated protein in yeast and exported to the outside of the cell. Screening for high affinity 
binding events can be accomplished using FACS.[58] Our lab utilized yeast display to develop a 
polyclonal mixture of helix-grafted display proteins that inhibit HIV membrane fusion and 
potentially prevent resistance of the virus to the protein cocktail.[55, 63] The library generated 
peptide mimics with improved affinity (~2.6-6.2 nM) that retained HIV-1 inhibition across three 









 Helical ligands are ubiquitous in nature and have a profound impact on disease state of 
cellular function and signaling. Because of this, research has focused on probing and inhibiting 
these interactions involving an α-helix. The most common method for probing these PPIs is to 
mimic the native α-helix either through production of a helical peptide or peptide mimic. Many of 
Figure 1.5 (A) Phage display schematic. Phage go through a cycle of creating diversity, 
biopanning for high affinity binders and amplification in E. coli. (B) Ribosome display 
schematic. DNA library is transcribed into RNA and translated on the ribosome where it 
remains tethered to the translated protein and enriched for high affinity binders before reverse-
transcribing RNA into DNA and amplifying the enriched library. (C) Bacterial display schematic. 
Protein libraries are fused to a membrane-associated bacterial protein and displayed on the 
outside of bacteria where they can be screened using FACS for high affinity binders.  (D) Yeast 
display schematic. Protein libraries are fused to a membrane-associated yeast protein (AGAII) 
and displayed on the outside of yeast cells where they can be screened using FACS for high 
affinity binders.   
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the mechanisms to develop a peptide mimic involve chemical synthesis which has the drawback 
of poor production yields and high production costs.  
Overcoming this challenge led researchers to utilize protein fusions to solubilize peptides. 
This includes fusions of hyperstable proteins with protease cleavage sites to express the peptide in 
a common bioproduction host and then isolate the peptide post-purification. Fusions solve the high 
synthetic production costs, however peptides without a tertiary structure have a limited shelf life 
and poor pharmacokinetics due to their susceptibility to proteolytic degradation and rapid in vivo 
clearance. Protein fusions have extended into the realm of ‘protein grafting’ by taking a native 
protein containing a solvent-exposed helix and mutating the native helix to resemble the peptide 
of interest. Proteins used as scaffolds in protein grafting have ranged from miniature proteins and 
coiled-coils to larger tertiary structures like affibodies, ankyrin motifs and PH domains. Grafting 
on the native peptide-of interest aides in probing the helical PPI, but much of the time the native 
binding interaction has modest affinity for its receptor.  
Evolving helical interfaces has bridged the gap from the modest affinity of the initial 
interaction to a much tighter binder, able to outcompete the wildtype peptide. Typically, phage 
display has been utilized for screening protein libraries. This has yielded improved affibodies and 
other helical bundles. Yeast display has also emerged as an impressive screening method as it 
contains chaperones to aide in protein folding and generally enriches for proteins with improved 
stability and expression as well as tighter affinity for the target. A variety of novel techniques for 
screening protein libraries are being utilized for protein evolution including ribosome display and 
bacterial display.  
The combined progression in generating helical mimics that display improved binding 
affinity and in vivo stability has led to the research in this dissertation. This work takes the current 
15 
 
concepts of helical stabilization and improves upon the concepts, focusing on HIV-1 membrane 
fusion as a case study. As technology develops, targeting PPIs involving α-helices will be at the 
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Helix-grafted Display: HIV-1 as a Case Study for Helical 




In this work, the protein engineering design and initial analysis was done by myself. Rachel 
Tennyson aided me in cloning and protein purification as well as protein expression and binding 
analysis experiments. I also carried out serum stability assays and ELISA experiments.  
 
2.1 Introduction 
  The ongoing discovery of new drug therapies is of vital importance to human health. The 
traditional pharmaceutical paradigm for this discovery centers on small molecules binding to well 
defined protein pockets, typified by enzyme active sites. However, there remain countless 
important targets largely beyond the reach of this strategy, principally due to extended contact 
surfaces. Such interactions are often collected under the heading of “protein–protein interactions” 
or PPIs.[1, 2] 
 A medicinally significant subset of these PPIs feature binding of one protein to an exposed 
helix on another, which has sparked considerable interest in the synthetic replication of helical 
epitopes as a route to novel therapeutics. Various strategies have been employed, including 
oligomeric organic scaffolds that project side chains along appropriate vectors,[3-5] covalently 
constrained (or “stapled”) peptides,[6-9] and helical “foldamers”[10-14] employing natural or  
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 Reprinted with permission from: 
Walker, S.N., Tennyson, R.T., Chapman, A.M., Kennan, A.J., McNaughton, B.R., GLUE That Sticks to HIV: A 
Helix‐Grafted GLUE Protein That Selectively Binds the HIV gp41 N‐Terminal Helical Region, ChemBiochem, 




unnatural backbone architectures. Each has produced effective agents, but all require nontrivial 
synthetic effort and expense. 
 A more accessible suite of ligands might be had by exploiting the flexibility and feasibility 
of protein expression. If one could identify a scaffold protein bearing a helix with at least one 
solvent-exposed face, and if that protein was simple and stable enough to facilitate easy expression 
and tolerate varying the exposed helical residues and helix length, it could serve as a generic 
scaffold upon which to graft any desired helical interface. The result would be a protein graft in 
which residues critical to recognition of a particular epitope are mutated onto the host protein in 
appropriate positions along the solvent-exposed helix. The general concept of grafting is an 
established method for mimicking protein surfaces.[15-19] 
 In this proof-of-concept manuscript, we report successful application of our specific “helix-
grafting” technique to a PPI crucial for HIV infection. The HIV fusion protein gp41 operates in 
part by binding a C-terminal helix (Cpeptide) onto a trimeric N-terminal helix in a coiled-coil 
arrangement. We show that grafting of gp41 Cpeptide residues onto the exposed helical face of a 
suitable protein scaffold affords a new ligand that expresses well in E. coli, exhibits excellent 
serum stability, and is capable of replicating the native interaction. Following initial attachment to 
a target cell, HIV entry is affected by fusion of the respective cell membranes, mediated by 
gp41.[20, 21] In the prefusogenic state, gp41 is trimerized, and an N-terminal fusion peptide from 
each subunit inserts into the target membrane. The protein then undergoes a conformational 
rearrangement in which the Cpeptide packs as an antiparallel helix against the surface of the N-
terminal Heptad Repeat (NHR) trimer.[22, 23] Anchoring of the respective protein termini into 
viral and cell membranes ensures that this rearrangement requires membrane juxtaposition and 




either the Npeptide helix or Cpeptide helix (some as short as 12–16 residues) have been shown to 
bind the coiled-coil and inhibit membrane fusion by HIV.[24-31] The best known of these, 
enfuvirtide (marketed as Fuzeon™), consists of 36 residues and is an FDA-approved treatment 
(Figure 2.1B).[32, 33] However, like other short peptide drugs, its chemical synthesis is 
extraordinarily expensive and it exhibits poor serum stability (t1/2 ~3.8 h).[34] We reasoned that a 





Figure 2.1 (A) HIV viral fusion by formation of a prefusogenic state leading to a trimer-of-
hairpins assembly involving the N-terminal helical region (NHR, tan) and the C-terminal helical 
region (CHR, density blue) of gp41. Fusion inhibitors bind to the prefusogenic state and 
prevent the formation of the trimer-of-hairpins assembly. (B) Crystal structure of the NHR/CHR 
monomeric complex (PDB ID: 1AIK). Sequences used as fusion inhibitors are denoted as C-




2.2 Helix-grafted Display of Cpeptide on GRAM-Like Ubiquitin-binding in EAP45 (GLUE)  
    In designing our first-generation helix-grafted protein, we focused on a Pleckstrin 
homology (PH) domain called GLUE (GRAM-Like Ubiquitin-binding in EAP45, Figure 2.2A, 
gray), which is derived from a subunit of the endosomal sorting complex.[35] Like other members 
of the PH family, the GLUE domain contains a C-terminal amphipathic helix resting in a cleft 
formed by two opposing β-sheets, with one face presented to solvent. This relatively rare 
arrangement is well suited to serve as a helix-grafting scaffold. Although the native GLUE helix 
is only 16 residues, known structures of other PH domains with helices up to 29 residues suggested 
that it could be extended to a length comparable to the Cpeptide without structural compromise. 
In addition to its well-positioned helix platform, GLUE is a relatively small (~15 kDa) and stable 
protein. Finally, native GLUE function relies on an affinity for phospholipids that can be abolished 
by a single Arg107Ala mutation, making it suitable for future intracellular targets without fear of 
disrupting lipid trafficking.[35] 
 We began by aligning the native helix on GLUE (Figure 2.2A, grey) with a single C-
peptide helix from gp41 (Figure 2.2A, density blue). Backbone atoms from the GLUE helix (PDB 
ID: 2CAY) were aligned with the corresponding number from the N-terminal segment of the gp41 
C-peptide (PDB ID: 1AIK) by using the PyMOL pair_fit algorithm. The overlay was very good 
(RMSD of 0.44  over 60 atoms), and it allowed us to confidently select six positions on the GLUE 
helix at which we could install side chains from the gp41 sequence in such a way as to replicate 
their native three-dimensional positions. We then extended the helix by genetically extending a 
pure gp41 sequence to the C-terminus of GLUE (Figure 2.2A), such that the total length of the 
new helix was appropriate for binding to the trimeric N-terminal coiled-coil. The helix-grafted 




a tryptophan on the grafted helix. The phenylalanine was mutated to an alanine (F24A) to prevent 
any folding constraints from the van der waals forces (Figure 2.2B, red spheres). The final 
sequence was expressed as a soluble protein in E. coli (Figure 2.2C).  
 
2.3 Structural Analysis of Helix-grafted Display for Developing Stabilized Helical Ligands 
 We characterized both wild-type GLUE (wtGLUE) and the helix-grafted variant (referred 
to as GLUE-Cpep herein) by circular dichroism (CD) to probe for macroscopic structural changes 
(Figure 2.3A). Both proteins display a similar overall signal, suggesting that the grafting process 
does not compromise the GLUE domain fold. As one element of our design was the expectation 
that a well-folded protein domain would exhibit improved serum stability compared to an isolated 
Figure 2.2 (A) Wild-type GLUE (gray) and gp41 C-peptide (dark blue). Sequences of the GLUE 
helix and the corresponding region of the gp41 helix are shown in gray and blue, respectively. 
Spheres indicate the C positions for each. Helix-grafted GLUE-Cpep, produced by backbone 
alignment of the independent structures. Spheres indicate C positions of GLUE residues 
mutated to those from gp41 (also color coded in the sequence). (B) Steric hindrance from 
residue F24 mutated to F24A to relieve folding strain. (C) Helix-grafted GLUE-Cpep (with F24A 




short peptide, we next conducted a serum stability test using a standard assay.[36] FLAG-tagged 
GLUE-Cpep, incubated with human serum for up to 12 h, showed no appreciable degradation by 
western blot analysis (Figure 2.3B). This supports a significant serum stability enhancement for 
the grafted protein compared to isolated peptides such as enfuvirtide.  
 
 
2.4 Functional Analysis of Helix-grafted Display for Developing Stabilized Helical Ligands 
Direct analysis of the binding interaction between GLUE-Cpep and the NHR receptor by 
simple mixing of the two components is complicated by several factors: proper self-assembly of 
the N-terminal peptide, the potential for one, two, or three GLUE-derived ligands per complex, 
and the known susceptibility of unbound N-peptide trimers to aggregation/precipitation. 
Fortunately, these challenges have long been recognized, and several solutions exist. We chose to 
use a construct called 5-helix, based on initial work by Kim and co-workers.[37] It solves the 
problem of multiple equilibria and binding sites by covalently tethering five of the six subunits 
with short Gly/Ser loops. Thus, a single polypeptide contains three copies of the NHR domain and 
two C-peptides, such that when folded, it features the coiled-coil with two of its binding sites 
Figure 2.3 (A) Circular dichroism spectra for wildtype GLUE (•) and GLUE-Cpep (•). Wave 
traces show similarities in secondary structure with increased helicity for the helix-grafted 
GLUE-Cpep. (B) Western blot of FLAG-GLUE-Cpep prior to incubation with human serum 




already occupied and just a single exposed interface (Figure 2.4A). Throughout, we used 5-helix 
as a receptor to assess complex formation with GLUE-Cpep. Initial CD characterization of the 
GLUE-Cpep/5-helix complex demonstrates binding-induced gains in helicity and thermal 
stability. The wavelength spectrum (Figure 2.4B) exhibits a notably deeper signal for the 1:1 
mixture than for either component alone, and the corresponding melt data (Figure 2.4C) reveals a 
dramatic increase in thermal stability, as evidenced by a significant shift of the overall melting 
curve, though the change in Tm is more modest (observed Tm values of ~77, ~79, and ~83°C for 
5-helix, GLUE-Cpep, and the complex, respectively). The melting transition for the 1:1 sample is 
also highly cooperative, further supporting a well-defined assembly. 
Having validated the GLUE-Cpep/5-helix interaction, we moved on to probe its viability 
in more complex environments. Binding in living cells (E. coli) was first assessed by split-
superpositive green fluorescent protein (split-spGFP) reassembly, a technique we recently 
reported.[38, 39] E. coli were co-transformed with plasmids encoding 5-helix fused to the N- 
terminal half of spGFP (N-spGFP-5-helix) and one of two C-spGFP fusions: GLUE-Cpep or the 
gp41 C-peptide by itself. Interaction-dependent reassembly of GFP fragments (to generate a 
fluorescent signal) was measured by flow cytometry. Cells expressing either ligand construct are 
highly fluorescent, in contrast to a control with nothing fused to C-spGFP (Figure 2.4D). We 
further characterized this interaction by using ELISA. The grafted GLUE (GLUE-Cpep) bound 5-
helix with slightly better affinity than the native C-peptide, whereas the wild-type GLUE exhibits 
no appreciable affinity thus confirming the need for the grafted domain (Figure 2.4E). This ELISA 
signal, indicating binding to a biotinylated 5-helix (Supplemental Figure 6.1A), was observed even 
for a GLUE-Cpep sample that was pre-incubated with human serum for up to 12 h (Figure 2.4F), 




experiments show that the helix-grafted GLUE binds 5-helix in the context of a complex cellular 
milieu, in a manner comparable to the native ligand and with improved serum longevity compared 
to FDA-approved Enfuvirtide (~3.8 h). 
Binding selectivity was assessed by measuring the amount of protein that was copurified 
from E. coli expressing an untagged GLUE-Cpep (~17.1 kDa) and His6-tagged 5-helix (~25.4 
kDa). The tagged 5-helix copurified with a single protein, which was identified as GLUE-Cpep by 
mass spectrometry (Supplemental Figures 6.1B and 6.1C). The similar amounts of each copurified 
protein, as determined by densitometry measurements of each protein band, further indicated that 
the complex involved a 1:1 ratio of proteins (data not shown). The relatively miniscule levels of 
other copurified cellular proteins indicates excellent selectivity for this interaction, even in a 





Figure 2.4 (A) Depiction of 5-helix, a single protein consisting of three copies of gp41 N-
peptide (beige) and two copies of gp41 C-peptide (purple). When folded, this protein presents 
a single binding cleft (translucent column with dashed border) for a Cpeptide or Cpeptide mimic 
(purple column with dashed border). (B) Circular dichroism wave spectra of GLUE-Cpep (•), 
5-helix (•), and a premixed 1:1 ratio of 5-helix and GLUE-Cpep (◦) (C) Circular dichroism 
thermal melt data at 222 nm for GLUE-Cpep (•), 5-helix (•), and a premixed 1:1 ratio of 5-helix 
and GLUE-Cpep (◦) showing temperature-dependent unfolding with increased stability for the 
complex (Tm ~79, ~77, and ~83°C for GLUE-Cpep, 5helix and the 1:1 complex). (D) Flow 
cytometry histograms for E. coli following split-spGFP reassembly experiments. (-) N-spGFP-
5-helix/C-spGFP, (-) N-spGFP-5-helix/C-spGFP-Cpep, (-) N-spGFP-5-helix/C-spGFP-GLUE-
Cpep. (E) in cellulo ELISA signal from E. coli cell lysate that expressed empty pETDuet 
plasmid, or pETDUET encoding for His6-5-helix and FLAG-wtGLUE, GLUE-Cpep, or 
Cpeptide. wtGLUE exhibits no appreciable signal while Cpeptide and GLUE-Cpeptide display 
appreciable binding. (F) in vitro ELISA on streptavidin (SA) coated plates with immobilized 
biotin-5-helix and FLAG-GLUE-Cpep incubated with denatured or active human serum. 




2.5 Conclusion  
 In conclusion, we have demonstrated that the solvent exposed C-terminal α-helix of the 
GLUE protein scaffold can be dramatically modified and extended, so as to mimic the function of 
the gp41 C-peptide. ELISA and copurification data indicate that GLUE-Cpep selectively binds 5-
helix, a protein that mimics the native C-peptide receptor. Unlike the isolated C-helix of 
enfuvirtide, GLUE-Cpep is soluble and well-folded in aqueous solution at room temperature (~25 
˚C) and is resistant to degradation in human serum at physiological temperature (~37 ˚C). Thus, 
this protein drug lead overcomes challenges faced by traditional peptide reagents and could 
represent a new reagent for inhibition of HIV entry. Additionally, helix-grafting onto PH and PH-
like domains, such as GLUE, might be a general approach to the development of new reagents of 
interest to a diverse set of diseases that rely on helix-driven assembly. Finally, GLUE-Cpep serves 
as a starting point for the generation of higher affinity and more selective mutants through the 
application of high-throughput screening or selection methods. Such experiments are currently 




Genes were cloned into pETDuet-1 using restriction enzymes BamHI and PacI, downstream of a 
His6x tag and transformed into BL21s (DE3). Cells were grown in 2.5 L LB cultures containing 
50 μg/mL carbenicillin at 37 °C to OD600=0.5 and induced with 1 mM IPTG at 25 °C overnight. 
Cells were then collected by centrifugation, resuspended in Tris buffer (20 mM Tris pH 7.4, 100 
mM NaCl, 10 mM (NH4)2SO4) and stored at -20 °C. Frozen pellets were thawed and sonicated 




and the supernatant was mixed with 1 mL of Ni-NTA agarose resin for 1 hour at 4 °C. The resin 
was collected by centrifugation (4,750 rpm, 10 min.). The resin was sequentially washed with 50 
mL of buffer containing 20 mM imidazole, 10 mL buffer containing 50 mM imidazole, and 5 mL 
buffer containing 100 mM imidazole. The protein was then eluted with 4 mL buffer containing 
400 mM imidazole. The proteins were dialyzed against Tris buffer and analyzed for purity by SDS-
PAGE. Purified protein concentrations were quantified using Beer’s Law at an absorbance of 280 
nm, following standard practice. In general, GLUE-Cpep was expressed as a soluble protein (~3 
mg/L of E. coli culture) 
Resolubilization from Inclusion Bodies 
5Helix-His was cloned into a modified pETDuet-1 vector using restriction enzymes NdeI and KpnI 
and transformed into BL21s (DE3). Cells were induced to express 5Helix-His6x and lysed as 
described above. The lysate was cleared by centrifugation (15,000 rpm, 30 min.) and the 
supernatant discarded. The pellet was washed twice with Tris buffer containing 0.5 % Triton® X-
100 and once with Tris buffer. The pellet was resuspended in urea buffer (Tris buffer with 8 M 
urea and 10 mM imidazole) to resolubilize the inclusion bodies and cleared by centrifugation 
(9,500 rpm, 30 min.) The supernatant was mixed with 1 mL of Ni-NTA agarose resin for 1 hour 
at 4 °C. The resin was collected by centrifugation (4,750 rpm, 4 min.). The resin was washed with 
50 mL of urea buffer and eluted with 40 mL of urea elution buffer (Tris buffer with 6 M urea and 
100 mM imidazole) into 500 mL Tris buffer by gravity dripping while stirring to refold the protein. 
The 540 mL elution was run through a column containing 1 mL of Ni-NTA agarose resin and 
eluted with 5 mL Tris buffer containing 400 mM imidazole. The protein was then eluted with 4 




for purity by SDS-PAGE and analyzed for refolding by CD. Purified proteins were quantified 
using Beer’s Law at an absorbance of 280 nm. 
Circular Dichroism 
Proteins were purified as described above. Separately, each protein was diluted to 7-9 μM in Tris 
buffer. Wavelength data are the average of three scans from 250 nm to 200 nm in 1 nm steps at 25 
°C. Thermal denaturation experiments at 222 nm were run from 0 to 90 °C in two-degree steps at 
a two-degree/minute rate of increase with one-minute equilibration and data averaging at each 
temperature. Tm values were obtained from minima of the first derivative of θ versus 1/T plots. 
Serum Stability Assay 
Using a previously described assay for serum stability, GLUE-Cpep was cloned into pET-28a(+) 
vector with an N-terminal FLAG tag (DDDDK) using restriction enzymes NdeI and HindIII. The 
completed construct was transformed into BL21s (DE3) and purified as described previously. 1 
mL of RPMI supplemented with 25 % (v/v) of human serum was equilibrated at 37 °C. GLUE-
Cpep was added to the solution to obtain a final concentration of 50 μg/mL and incubated at 37 
°C. At known time intervals of 0.5, 1, 2, 4, 8, or 12 hours, 100 μL of the reaction solution was 
removed and denatured at 94 °C for 20 minutes and stored at -80 °C. Samples were separated by 
SDS-PAGE and transferred to a nitrocellulose membrane via an iBlot western blotting apparatus. 
The membrane was washed with PBS and incubated in LI-COR Blocking Buffer at 4 °C for 1 
hour. The membrane was then incubated with a mouse anti-DDDDK antibody (anti-FLAG) in LI-
COR Blocking Buffer for 1 hour at 4 °C. The membrane was washed 3x with PBS containing 0.1 
% Tween-20, and then incubated with a IRDye 800CW Goat anti-mouse IgG-LI-COR secondary 
antibody in LI-COR Blocking Buffer for 1 hour at room temperature. The membrane was washed 




Split-Superpositive GFP (split-spGFP) Reassembly Assay 
N-terminal superpositive GFP genetically tethered to the 5helix was cloned into pETDuet-1 using 
restriction enzymes BamHI and PacI. The completed construct was transformed into BL21s (DE3) 
and the cells were made electrocompetent via standard protocols. Separately, GLUE-Cpep and C-
peptide tethered to the C-terminal fragment of superpositive GFP were independently cloned into 
pBAD vector using restriction enzymes NcoI and BsrGI. Constructs were electroporated into 
electrocompetent BL21s (DE3) containing the N-terminal superpositive GFP plasmid, pulsing at 
1.8 kV in a 1 mm cuvette. Cells were allowed to recover in SOC media at 37 °C for 1 hour, and 
then plated onto agar plates containing carbenicillin and kanamycin. Individual colonies were 
picked and passaged once, followed by induction at 37 °C with 1 M IPTG and 0.2 % arabinose 
when cultures reached an OD600 of 0.5. After 6 hours, cells were spun down and resuspended in 5 
mL PBS. GFP fluorescence was measured by MoFlo Flow Cytometer. 
In cellulo ELISA 
Separately, wtGLUE, GLUE-Cpep, and the Cpeptide were cloned into MCS1 of pETDuet-1 with 
FLAG tags using restriction enzymes NcoI and NotI. The 5helix with a C-terminal His6x tag was 
cloned into MCS2 of pETDuet-1 using restriction enzymes NdeI and KpnI. Completed constructs 
were transformed into BL21s (DE3). Cells containing the co-expressed pair were inoculated and 
induced as described previously. Cells were spun down and resuspended in lysis buffer (20 mM 
Hepes pH 7.5, 100 mM NaCl), lysed by sonication, and spun down to remove cell debris. Cleared 
lysates were incubated on clear Ni-NTA coated plates for 1 hour at room temperature and washed 
4x with 200 μL wash buffer (20 mM Hepes pH 7.5, 150 mM NaCl, 0.05 % Tween-20, 0.01 mg/mL 




for 1 hour at room temperature, followed by 4x 200 μL washes. Colorimetry was developed using 
TMB-One substrate and absorbance was measured at 655 nm on a SynergyMx Microplate Reader. 
ELISA Binding Assay in Human Serum 
GLUE-Cpep was cloned into pET-28a(+) with an N-terminal FLAG tag using restriction enzymes 
NdeI and HindIII. 5helix was cloned into pETDuet-1 with an N-terminal AviTag and a C-terminal 
His6x tag using restriction enzymes NcoI and PacI. The completed constructs were transformed 
into BL21s (DE3) and purified as described previously. AviTag-5helix was conjugated to biotin 
using Avidity BioMix protocols and purified BirA Protein Ligase at 1.0 mg/mL. Biotin 
conjugation was confirmed by Mass Spectrometry. Separately, 5 mL of RPMI supplemented with 
25 % (v/v) human serum, 5 mL of boiled RPMI supplemented with 25 % (v/v) of human serum, 
and 5 mL of (1x) PBS were equilibrated at 37 °C. GLUE-Cpep was added to each solution to a 
final concentration of 50 nM and incubated at 37 °C for 4 or 12 hours. 200 μL wash buffer (1x 
PBS pH 7.4, 0.1 % Tween-20, 0.02 mg/mL BSA) was incubated on clear streptavidin coated plates 
for 1 hour at room temperature to block. 100 μL of Biotinylated 5-helix at a concentration of 10 
μg/mL was incubated for 1 hour at room temperature and washed 4x with 200 μL wash buffer. 
100 μL of human serum-incubated GLUE-Cpep solutions were incubated on the plates for 1 hour 
at room temperature and washed 4x with 200 μL wash buffer. HRP-conjugated mouse anti-
DDDDK antibody in LI-COR blocking buffer was incubated for 1 hour at room temperature, 
followed by 5x 200 μL washes. Colorimetry was developed using TMB-One substrate and 
absorbance was measured at 655 nm on a SynergyMx Microplate Reader.  
Lysate Ni-NTA Pulldown Assay 
GLUE-Cpep was cloned into MCS1 of pETDuet-1 using restriction enzymes NcoI and NotI. The 




enzymes NdeI and KpnI. Completed constructs were transformed into BL21s (DE3). Cells 
containing the co-expressed pair were inoculated and induced as described previously. Cells were 
spun down and resuspended in lysis buffer (100 mM NaCl, 20 mM Tris pH 7.4, 10 mM 
(NH4)2SO4), lysed by sonication, and spun down to remove cell debris. Cleared lysate was 
incubated with 200 μL Ni-NTA agarose resin for 1 hour. Ni-NTA agarose was washed with 8 mL 
lysis buffer containing 10 mM imidazole. Proteins were eluted with 500 μL lysis buffer containing 
400 mM imidazole. The pulldown was analyzed by SDS-PAGE and confirmed by Mass 
Spectrometry. 
 
2.7 Sequences of Proteins Used in this Work 





























5 Helix-His6x  
(same as that used in Circular Dichroism) 






























For lysate Ni-NTA pulldown assay experiments 
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Helix-Grafted Pleckstrin Homology Domains  




In this work, led by second year graduate student Rachel Tennyson, I assisted in gene 
construction and molecular cloning, as well as experimental design of helix-grafting and planning 





 Essentially every biological process relies heavily on a cascade of protein–protein binding 
events.[1] The macroscopic architecture and complex molecular diversity of protein ligands or 
receptors often allows them to engage partners whose large surface area and spatially disperse 
recognition features hinder discovery of traditional small-molecule ligands. The ubiquity of such 
supramolecular targets underscores the need for a complementary discovery approach that 
produces macromolecular agents capable of specific protein recognition. Indeed, biologics 
constitute a rapidly expanding sector of our pharmaceutical arsenal. With an eye toward the vast 
array of protein–protein interfaces (PPIs) comprised of an -helix bound into a surface cleft, we 
recently developed a method for helical ligand discovery conversed in Chapter 2.[2]  
We began with the premise that isolated helical fragments were themselves poor starting 
points for either discovery or application of new ligand sequences. As discussed in detail in 
                                                          
1
 Reprinted with permission from: 
Tennyson, R.L., Walker, S.N., Ikeda, T., Harris, R.S., Kennan, A.J., McNaughton, B.R., Helix-Grafted Pleckstrin 
Homology Domains Suppress HIV-1 Infection of CD4-Positive Cells, ChemBiochem, 2016, 17, 1892 
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Chapter 1, typical helix lengths at PPIs are relatively short, which complicates both production 
and stability of the excised sequences. Short peptides are difficult to express recombinantly, and 
their chemical synthesis on a therapeutically viable scale remains a significant challenge. Even 
when successful, it dramatically increases the cost of treatment.[3] Meanwhile, such ligands are 
typically unfolded, significantly enhancing their susceptibility to non-specific degradation in 
vivo.[3] These shortcomings have fueled the search for alternative structures that mimic native PPI 
ligands.[4-10] Native sequences have been fitted with conformational constraints (hydrogen bond 
surrogates, “staples”) or backbone modifications (β-peptides), among other strategies. Though 
often successful, these approaches require nontrivial chemical synthesis that limits throughput and 
elevates costs. Alternatively, stably folded peptides or small proteins with intrinsic helical domains 
have been resurfaced (or grafted) with key contact residues from a particular PPI, although the 
expression and solubility of these proteins has, in some cases, been poor.[11] Though the final 
ligands are often still prepared synthetically, the all-natural sequences can be optimized by using 
directed evolution techniques. 
In developing a general scaffold for helix display, we sought to identify a protein fold that 
presented a properly folded -helix within the confines of a larger structure, in such a way as to 
permit direct receptor access to one helical face. Ideally, the basic scaffold would be readily 
expressible in soluble form, tolerant of mutation and/or extension of the helix (to permit sequence 
optimization), and protective against rapid helix degradation. Once identified, this basic 
framework could then serve in plug-and-play fashion as the starting point for optimizing a broad 
range of future PPI modulators. Our initial scaffold search identified pleckstrin homology (PH) 
domains as a plausible starting place. PH domains are found in a broad family of lipid-binding 
proteins whose fold displays a single α-helix atop a pair of -sheets, such that one helix face is 
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solvent exposed.[12-14] We reasoned that such structures might serve as a good foundation for 
helix-grafted systems, in which solvent-exposed helix residues are mutated and/or the native helix 
is extended so that they mimic disease-relevant helical ligands. The reliability of expression, folded 
state stability, and potential for evolving optimized sequences would make such constructs 
excellent leads for new protein ligand therapeutics. Our initial proof-of-principle report 
demonstrated that a helix-grafted PH domain could replicate binding of the native helical ligand 
to an HIV fusion protein model.[2] Here, we explored the scope of viable PH scaffolds and 
generated constructs capable of inhibiting HIV infection in a live-virus assay. 
 
3.2 Optimizing the Pleckstrin Homology Domain Scaffold for Helix-grafted Display  
In the previous chapter, we described using the PH domain from a yeast-derived protein 
called GLUE as a scaffold for gp41 Cpeptide helix-grafted display (Figure 3.2A).[2] Surface-
exposed GLUE helix residues were mutated to match those of gp41, and the helix was extended 
to match the native C-peptide length by using the pure gp41 sequence.[15-21] The resulting grafted 
protein was shown to be stable, well folded, and capable of recognizing a standard gp41 model 
with fidelity comparable to that of the wild-type peptide, as measured by split-GFP reassembly, 
ELISA, and copurification assays. It also retained much of its efficacy even after a 12 h exposure 
to human serum, supporting our initial design hypothesis that positioning the ligand within a larger, 
stably folded structure would protect against rapid degradation.[19, 20] Although our initial effort 
was quite successful, we were interested both in probing the scope of our chosen scaffold and in 
testing our gp41 mimics in more demanding environments. We began by selecting a collection of 
nine PH domains, favoring those of human origin to potentially mitigate downstream 
immunogenicity. The set of PH domains with reported X-ray structures exhibited considerably 
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diversity in helix length, total protein size, and percentage of total residues involved in the helix. 
As we were unsure how each of these variables might impact expression, viability and/or helix 
presentation, we chose an array of candidates covering a range of characteristics (Figure 3.2B, 
Table 3.2). Although the canonical PH fold presents a C-terminal helix, the engulfment and cell 
motility (ELMO)-1 domain has the added benefit of an additional N-terminal helix,[22] providing 
the option to display partially structured ligands that are helical at both termini. 
Our initial screen for scaffold suitability was simple expression of the wild-type proteins, 
as well-expressing systems were expected to better tolerate modification. At this stage, four of our 
nine next generation candidates were eliminated based on poor expression (Figure 3.2C and 
Supplemental Figure 6.2A). The remaining candidates, including our original GLUE scaffold, 
were grafted with the gp41 Cpeptide sequence. We tested both the N- and C-terminal ELMO sites 
(Figure 3.2D) and were satisfied to discover that both constructs expressed admirably (Figure 3.2E 
and Supplemental Figure 6.2A). Although other sequences also worked, ELMO seem to present 
the most flexibility and thus the most potential to serve as a general scaffold for a series of future 




Table 3.2 Candidate PH Domains with a range of characteristics from protein size to percent 
helicity. Many of the selected scaffolds were of human origin to mitigate potential 






Figure 3.2 (A) Helix-grafted display strategy for generating stable Cpeptide mimics on a PH 
domain. The native ligand (density blue, PDB: 1AIK) is overlaid on the scaffold protein (grey, 
PDB: 2CAY), and solvent-exposed scaffold residues are mutated to those of the displayed 
ligand (density blue spheres). (B) Candidate PH domain scaffolds examined in this work. PDB: 
1P6S (AKT2), 2ELA (APPL1 PTB), 2ELB (APPL1 PH), 1J0W (DOK5), 2DYN (dynamin), 1I2H 
(homer), 2VSZ (ELMO), 1UNP (PKB), 2I5F (Plekstrin). (C) Expression levels of soluble 
wildtype scaffolds following purification by His6/Ni-NTA column. Error bars indicate standard 
deviation of three experiments. (D) Models of N-terminal (C26-ELMO) and C-terminal (ELMO-
C34) helix grafts on the ELMO scaffold. Grafted gp41 positions are density blue (spheres 
indicate mutated -carbon positions). Soluble expression levels (following purification by 
His6/Nickel-NTA column purification).  
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3.3 Optimizing the Cpeptide Helical Graft    
Having centered on ELMO as our most promising display vehicle, we sought to test its 
ability to effectively present a collection of different Cpeptide sequences, while at the same time 
probing the sensitivity of our grafted constructs to alterations in ligand sequence. Although the 
C34 peptide used in our original helix-grafted ligand is taken from a partially overlapping region 
of gp41 as Enfuvirtide (T20), a significant portion of each sequence is unique. We thus sought to 
test grafting capabilities of both sequences, in addition to the longer one formed by their union 
(C46, Table 3.3). To test the intrinsic flexibility of N- versus C-terminal display, we prepared 
ELMO scaffolds grafted at either terminus (Lig-ELMO or ELMO-Lig), with C34, T20, and C46. 
We were especially interested in probing the role of the N-terminal WWI triad on C34, the side 
chains of which bind into a deep and highly conserved hydrophobic groove on the NHR trimer 
surface. The absence of this interaction in T20 (the sequence of which is shifted more toward the 
C-peptide C terminus) perhaps reduces barriers to acquired resistance (Table 3.3). 
 
The C-terminal grafts were prepared as before, with five solvent-exposed positions on the 
native ELMO helix mutated corresponding to those of the HIV sequence, and the C-terminus of 
the protein extended by the appropriate amount by using the remaining gp41 sequence. In contrast 
Table 3.3 Sequence of grafted gp41 Cpeptide ligand region for N- and C-terminal helix-grafted 
ELMO (designated lig-ELMO and ELMO-lig, respectively).  
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to the C-terminal ELMO helix, which rests atop the -sheets, the N-terminal helix is more fully 
exposed and of considerable length (nearly 20 residues). Fearing that long extensions of this helix 
might not be well tolerated, we prepared C34-ELMO and T20-ELMO by first excising 17 residues 
from the native helix and then simply fusing the appropriate sequence to the N terminus of the 
resulting protein (termed 17-ELMO). For C46-ELMO, three additional residues were trimmed, 
as the fused helix was longer (termed 21-ELMO). Finally, as a hedge against even those shorter 
helices proving unworkable, we prepared C26-ELMO, in which eight residues were deleted from 
the C-terminus of C34 before fusing it to the shortened 17-ELMO scaffold. To determine the 
impact of the N-terminal deletions from the core ELMO protein, we prepared both 17-ELMO 
and 21-ELMO on their own and were pleased to discover that both expressed even better than 
the wild-type platform (Figure 3.3A), so much so that we used 21-ELMO as the starting point 
for the C-terminal ELMO-Lig constructs.  
To establish that these various modifications had not compromised the overall protein fold, 
we examined each grafted protein by circular dichroism (CD) spectroscopy and compared the 
results to those of the base proteins (wild-type, 17-, and 21-ELMO). Plots of mean residue 
ellipticity versus wavelength for the C-terminal fusions were consistent with retention of overall 
structure and displayed expected helicity increases compared to the appropriate control. Similarly, 
all of the N-terminal fusion proteins exhibited increased helicity with respect to each of the starting 
proteins (Figure 3.3B). The helix-grafted proteins also displayed similar thermal unfolding 
profiles, consistent with retention of macroscopic structure (Figure 3.3C). Having determined that 
the HIV ligand mimic candidates were behaving as expected, we moved on to evaluate their 






3.4 Analysis of Optimized Helix-grafted Display Proteins  
As in the previous chapter, initial evaluations of ligand–receptor binding employed the 5-
helix construct that has been widely used for this purpose.[23, 24] The 5-helix protein links the 
central coiled-coil NHR trimer of gp41 and two CHR ligands into one sequence that assembles to 
present a single C-peptide binding site. This strategy both simplifies the interaction to be measured 
(making it a 1:1 rather than 3:1 complex) and eases solubility issues arising from exposing three 
copies of the significantly hydrophobic ligand-binding surface. 
We initially performed an in cellulo ELISA assay to assess binding in a complex cellular 
environment. Somewhat surprisingly, the native N-helix on ELMO, which we originally feared 
Figure 3.3 (A) SDS-PAGE gels after Ni-NTA column purification indicating protein expression 
levels of N- and C-terminal grafts to ELMO. The wildtype ELMO scaffold, 17-ELMO, and 21-
ELMO scaffolds were ran to compare protein expression of helical grafts to the protein 
scaffolds.  (B) Circular dichroism spectra of C- and N-terminal ELMO grafts. (C) Circular 
dichroism thermal melt data at 222 nm for N- and C-terminal grafts to ELMO, showing 
temperature-dependent unfolding with similar theral stability as compared to the original 
protein scaffolds.  
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might compromise expression efficiency, also had some nonspecific affinity for the 5-helix protein 
in this assay. However, this non-specific binding could be abrogated by truncation of the N-
terminal helix. Two shortened variants, 17-ELMO and 21-ELMO, with 17 or 21 residues 
removed from the N-terminal helix, respectively, showed substantially decreased affinity for the 
5-helix protein in the ELISA assay. The N-terminal fusion proteins generated stronger signals, 
particularly those with the WWI residues; C26-ELMO and C34-ELMO were better than C46-
ELMO, which in turn was better than T20-ELMO (Figure 3.4A). The two shorter fusion proteins 
gave signals comparable to the native C34 peptide. The C-terminal fusion proteins were weaker, 
with only 21-ELMO-C34 giving a signal even comparable to the analogous control scaffold 
(21-ELMO). 
We corroborated these in cellulo findings using a nickel pulldown assay. Cells were 
transformed and expressed with a plasmid encoding both the untagged ligand candidate and His-
tagged 5-helix protein, lysed, and exposed to Ni-NTA agarose resin. Consistent with the data from 
our ELISA experiment, SDS-PAGE analysis of the N-terminal fusions (Figure 3.4B, lanes 1–6) 
suggested that those bearing the WWI triad (lanes 3–5) were most effective at binding to the 5-
helix protein. The two shorter helices (C26 and C34) displayed the strongest retention, with a 
significant reduction for the longer C46-ELMO construct, and very little observable retention for 
T20-ELMO. The C-terminal fusion proteins (Figure 3.4B, lanes 7–12) exhibited a similar trend, 
albeit with an overall reduction in apparent affinity. Of the proteins with the native N-helix 
removed (denoted 21-ELMO-Lig), the C34 fusion (lane 10) was again more effective than either 
the C46 or T20 one (lanes 11–12), though the intact ELMO-C34 protein (lane 9) is perhaps even 
better due to the presence of the wildtype N-terminal helix which exhibits modest affinity for the 
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5-helix. Neither ungrafted truncation (17- or 21-ELMO) bound 5-helix appreciably in the 
copurification assay (Figure 3.4B). 
To better understand the complex involving 5-helix and our best-performing binders (C26-
ELMO and C34-ELMO), we used in vitro ELISA with biotin-5helix-his immobilized 
(Supplemental Figure 6.2B) to measure their dissociation constants (KD). Satisfyingly, these 
proteins tightly bound 5-helix (KD ~91 +/-8 nM and 6 +/-2 nM, respectively, Figure 3.4C). In 
addition to tightly binding the 5-helix protein, C26-ELMO and C34-ELMO were relatively stable 
in proteolytically active human serum. For both proteins, >50% of the full-length species was 




Figure 3.4 (A) in cellulo ELISA data showing binding between 5-helix-His6 and ELMO derived 
grafted proteins. (B) Ni-NTA co-purification of 5-Helix-His6 and either N-terminal (top) or C-
terminal (bottom) helix-grafted ELMO-derived proteins. (C) Dissociation constant (KD) for 
complexes involving the 5-helix protein and C26-ELMO or C34-ELMO (D) Western blot and 
densitometry analysis of C26-ELMO or C34-ELMO prior to human serum incubation (lane 1, 
time 0) and throughout incubation with human serum for up to 12 h.  
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3.5 HIV-1 Inhibition Using Optimized Helix-grafted Display Proteins  
Collectively, these initial experiments supported the notion that C-peptide grafted ELMO 
scaffolds were capable of recognizing the 5-helix model system, even in complicated cellular 
contexts, and further suggested that the most efficient of these systems were the shorter N-terminal 
fusions bearing the key WWI residues. Encouraged by these data, we set out to test the ability of 
helix-grafted gp41 mimics to inhibit infection by actual virus, according to a previously reported 
protocol.[25, 26] HIV-1 IIIB was administered to CD4-positive mammalian cells stably integrated 
with a plasmid that encodes the HIV-1 long-terminal repeat (LTR) upstream of green fluorescent 
protein (GFP). Thus, if HIV-1 successfully infects these cells, HIV-1 Tat/TAR-dependent 
transcription ultimately leads to GFP expression. The percentage of cells that express GFP 
(measured by flow cytometry) is thus equivalent to the percentage infected by the virus. Consistent 
with the ELISA and co-purification experiments, the N-terminal fusion proteins proved more 
effective by this measure as well (Figure 3.5A). Only the three WWI-containing helices (C26-, 
C34-, and C46-ELMO) exhibited significant inhibition, with the T20-ELMO protein proving 
largely ineffective. The longer C46 construct again lagged behind those with shorter helices, 
despite containing the WWI triad. The C-terminal fusion proteins (Figure 3.5B), as before, were 
less efficient overall, and only 21-ELMO-C34 was comparable to any of the N-terminal species. 
The scaffold controls (17- and 21-ELMO) did not materially inhibit infection, despite ELISA 
data suggesting at least moderate 5-helix affinity. Although both N- and C-terminal T20 fusions 
were largely ineffective in each of these assays, the isolated T20 peptide itself was significantly 
more potent in the live virus assay than any of our grafted systems. However, this in vitro assay is 
blind to the rapid degradation which compromises the in vivo efficacy of the T20 peptide and its 






Taken together, these results demonstrate the viability of our helix-grafting strategy as a 
method for presenting gp41 Cpeptide helices in a manner that allows them to efficiently recognize 
their intended receptor. Despite this success, opportunities for improvement remain. One plausible 
explanation for reduced efficacy of the longer C46 constructs (compared to C26/C34) is steric 
crowding, especially in the more complex in cellulo experiments with proximal lipid bilayers. It 
could be that further reduction in scaffold size is required for true generality moving forward. 
Additional affinity might also be obtained through directed evolution, optimizing the choice of 
receptor-facing residues. In the longer term, we are confident that the general strategy of helix-
grafted ligand display platforms will prove amenable to the discovery and optimization of new PPI 





Figure 3.5 (A) Suppression of HIV-1 entry by N-terminal fusion proteins and controls 17-
ELMO (gray); 21-ELMO (black); C26-ELMO (red); C34-ELMO (orange); C46-ELMO (green); 
T20-ELMO (blue); and C34 peptide (purple). (B) Suppression of HIV-1 entry by ELMO-derived 
C-terminal fusion proteins and controls: 21-ELMO (black); 21-ELMO-C34 (red); 21-ELMO-
C46 (orange); and 21-ELMO-T20 (green). 
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3.7 Methods    
Protein Expression and Purification 
Genes were cloned into pET using restriction enzymes BamHI and KpnI, downstream of a His6x 
tag and transformed into BL21s (DE3). Proteins containing a disulfide bond were transformed into 
Shuffle T7s. Cells were grown in 0.5 L LB cultures containing 50 mg/mL carbenicillin at 37 °C to 
OD600 =0.5 - 0.6 and induced with 1 M IPTG at 25 °C overnight. Cells were then collected by 
centrifugation, resuspended in Tris buffer (20 mM Tris pH 7.4, 100 mM NaCl, 10 mM (NH4)2SO4) 
and stored at -20 °C. Frozen pellets were thawed and sonicated with 1 second pulses for 2 minutes. 
The lysate was cleared by centrifugation (8,000 rpm 10 min.) and the supernatant was mixed with 
1 mL of Ni-NTA agarose resin for 30 min at 4 °C. The resin was collected by centrifugation (4950 
rpm, 10 min.). The resin was sequentially washed with 50 mL of Tris buffer containing 20 mM 
imidazole, 50 mL buffer containing 50 mM imidazole, and 10 mL Tris buffer containing 75 mM 
imidazole. The protein was then eluted with 2 mL Tris buffer containing 400 mM imidazole. The 
proteins were dialyzed against Tris buffer and analyzed for purity by SDS-PAGE. Purified protein 
concentrations were quantified using Beer’s Law at an absorbance of 280 nm, following standard 
practice. 
Resolubilization of 5-Helix Inclusion Bodies 
5Helix-His6x was cloned into a modified pETDuet-1 vector using restriction enzymes NdeI and 
KpnI and transformed into BL21s (DE3). Cells were induced to express 5 Helix-His6x and lysed 
as described above. The lysate was cleared by centrifugation (9,500 rpm, 30 min.) and the 
supernatant discarded. The pellet was washed twice with Tris buffer containing 0.5 % Triton® X-
100 and once with Tris buffer. The pellet was resuspended in urea buffer (Tris buffer with 8 M 
urea and 10 mM imidazole) to resolubilize the inclusion bodies and cleared by centrifugation 
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(9,500 rpm, 30 min.) The supernatant was mixed with 1 mL of Ni-NTA agarose resin for 1 hour 
at 4 °C. The resin was collected by centrifugation (4950 rpm, 4 min.). The resin was washed with 
50 mL of urea buffer and eluted with 40 mL of urea elution buffer (Tris buffer with 6 M urea and 
100 mM imidazole) into 500 mL Tris buffer by gravity dripping while stirring to refold the protein. 
The 540 mL elution was run through a column containing 1 mL of Ni-NTA agarose resin and 
eluted with 5 mL Tris buffer containing 400 mM imidazole. The protein was then eluted with 4 
mL buffer containing 400 mM imidazole. The proteins were dialyzed against buffer and analyzed 
for purity by SDS-PAGE and analyzed for refolding by CD.  
Circular Dichroism 
Proteins were purified as described above. Separately, each protein was diluted to 5-12 μM in Tris 
buffer. Wavelength data are the average of three scans from 250 nm to 200 nm in 1 nm steps at 25 
°C. Thermal denaturation experiments at 222 nm were run from 0 to 90 °C in two-degree steps at 
a two-degree/minute rate of increase with one-minute equilibration and data averaging at each 
temperature. Tm values were obtained from minima of the first derivative of θ versus 1/T plots. 
Serum Stability 
The helix-grafted C26-ELMO protein and helix-grafted C34-ELMO protein were cloned into a 
pET vector upstream of a C-terminal His6x-GS-FLAG tag (DYKDDDDK) using restriction 
enzymes NheI and BamHI. Proteins were purified as described above in Phosphate buffer (20 mM 
Na2HPO4 pH 7.4, 100 mM NaCl). 1 mL of RPMI supplemented with 25 % (v/v) of human serum 
was equilibrated at 37°C. C26-ELMO and C34-ELMO were each added to the solution to obtain 
a final concentration of 50 μg/mL and incubated at 37 °C. At known time intervals of 0.5, 1, 2,4, 
8, 12, 24 hours, 100 μL of the reaction solution was removed and denatured at 94 °C for 20 minutes 
and stored at -80 °C. Samples were separated by SDS-PAGE and transferred to a nitrocellulose 
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membrane via an iBlot western blotting apparatus. The membrane was washed with TRIS and then 
incubated in Blocking Buffer at room temperature for 1 hour. The membrane was subsequently 
washed 3x with TRIS containing 0.1 % Tween® 20. The membrane was then incubated with a 
mouse anti-DDDDK antibody (antiFLAG) in primary antibody wash buffer (TRIS with 5% BSA 
and 0.1 % Tween® 20) for 3 hour at 4 °C. The membrane was then washed 3x with TRIS 
containing 0.1 % Tween® 20, and then incubated with a IRDye 800CW Goat anti-mouse IgG 
secondary antibody in Blocking Buffer for 1 hour at room temperature. The membrane was washed 
with PBS containing 0.1 % Tween-20 and imaged using the Odyssey Classic Infrared Imager. 
Cell lysate ELISA 
Each helix-grafted ELMO protein, T20, and C34 were cloned into MCS1 of pETDuet-1 with 
FLAG tags using restriction enzymes NcoI and NotI. The 5-Helix with a C-terminal His6x tag was 
cloned into MCS2 of pETDuet-1 using restriction enzymes NdeI and KpnI. Completed constructs 
were transformed into BL21s (DE3). Cells containing the co-expressed pair were inoculated and 
induced in 10 mL LB cultures overnight. Cells were spun down and resuspended in 10 mL buffer 
(20 mM Tris pH 7.4, 100 mM NaCl, 10 mM (NH4)2SO4), lysed by sonication, and spun down to 
remove cell debris. Cleared lysates were incubated on clear Ni-NTA coated plates for 1 hr. at room 
temperature and washed 3x with 200 μL wash buffer (20 mM Tris pH 7.4, 100 mM NaCl, 10 mM 
(NH4)2SO4, 0.1% Tween® 20, 0.01 mg/mL BSA). HRP-conjugated mouse anti-DDDDK antibody 
in LICOR Blocking Buffer was incubated for 1 hr at room temperature, followed by 3x 200 μL 
washes (5 min.). Color was developed using TMB-One substrate and absorbance was measured at 





Lysate Ni-NTA Pulldown Assay 
Each helix grafted ELMO protein was cloned into MCS1 of pETDuet-1 using restriction enzymes 
NcoI and NotI. The 5-helix with a C-terminal His6x tag was cloned into MCS2 of pETDuet-1 
using the restriction enzymes NdeI and KpnI. Completed constructs were transformed into BL21s 
(DE3). Cells containing the co-expressed pair were inoculated and induced in 100 mL LB cultures 
overnight. Cells were spun down and resuspended in 5 mL buffer (100 mM NaCl, 20 mM Tris pH 
7.4, 10 mM (NH4)2SO4, lysed by sonication, and spun down to remove cell debris. Cleared lysate 
was incubated with 300 μL Ni-NTA agarose resin for 30 min. The resin was collected by 
centrifugation (4950 rpm, 10 min.). The resin was sequentially washed with 10 mL of Tris buffer 
containing 50 mM imidazole and 5 mL Tris buffer containing 100 mM imidazole. Proteins were 
eluted with 500 μL Tris buffer containing 400 mM imidazole. The pulldown was analyzed by 
SDS-PAGE. 
Biotinylation 
5helix-His6x was cloned into a pET vector containing an upstream Avitag™ 
(GLNDIFEAQKIEWHE)-GGSGGSGGT linker using restriction enzymes KpnI and PacI. The 
protein was resolublized from inclusion bodies as described above in Phosphate buffer (20 mM 
Na2HPO4 pH 7.4, 100 mM NaCl). His6x-BirA was cloned into pET using restriction enzymes 
NcoI and KpnI and purified as described above in Phosphate buffer. 300 mL of Avitagged™ 5-
Helix-His6x protein at 38 M was incubated with 6 mL of His6x-BirA at 1 mg/mL using Avidity® 
BirA biotin-protein ligase standard reaction kit at 30°C for 40 min. Biotinylation was confirmed 





In vitro ELISA 
The helix-grafted C26-ELMO protein and helix-grafted C34-ELMO protein were cloned into a 
pET vector upstream of a C-terminal His6-GS-FLAG tag (DYKDDDDK) using restriction 
enzymes NheI and BamHI. Proteins were purified as described above in Phosphate buffer (20 mM 
Na2HPO4 pH 7.4, 100 mM NaCl). The biotinylated Avitagged 5-helix-His6 (biotin-5helix) was 
prepared as described above in Phosphate buffer and diluted to 10 g/mL. Pierce® Streptavidin-
coated clear 96-well plates with a binding capacity of 5 pmol were pre-blocked with 200 L of 
wash buffer (Phosphate buffer, 0.5 mg/mL BSA, 0.1% tween® 20) for 1 hour. Biotin-5helix was 
immobilized on the streptavidin-coated plates by incubating 100 L of diluted protein for 1 hour 
at room temperature, followed by 4x 200 L washes (5 min). 100 mL of C26-ELMO or C34-
ELMO was incubated in various concentrations (10 pM, 100 pM, 1 nM, 5 nM, 10 nM, 20 nM, 25 
nM, 30 nM, 50 nM, 75 nM, 100 nM, 200 nM, 500 nM, 750 nM, 1 M, 10 M) for 1 hour, followed 
by 4x 200 L 4°C washes (5 min). (All concentrations of incubated helix-grafted protein were 
above ligand-depleting conditions for binding the 5 pmol immobilized biotin-5helix in each well). 
A 1:10,000 dilution of HRP-conjugated mouse anti-DDDDK antibody in LICOR Blocking Buffer 
was incubated for 1 hour at room temperature, followed by 4x 200 L 4°C washes (5 min). Color 
was developed using TMB-One substrate and absorbance was measured at 655nm on a SynergyMx 
Microplate Reader. 
Infectivity Assay 
HEK293T cells were maintained in DMEM supplemented with 10% fetal bovine serum (FBS) and 
0.5% penicillin/streptomycin (P/S). CEM-GFP cells were cultured in RPMI with 10% FBS and 
0.5% P/S. The procedure was virtually identical to a previously published variant. The HIV-1 IIIB 
C200 proviral expression construct has been described previously. Viruses were produced by 
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transfection of 3.0 μg of Vif-proficient proviral expression construct into 293T cells (3.0x106) 
using TransITⓇ-LT1 reagent. 48hr later, virus-containing supernatants were filtered by 0.45 μm 
filters and used to infect into 2.5x104 CEM-GFP cells with varying concentration of inhibitors. 
Infectivity (GFP+ cells) was measured by flow cytometry at 2 days post-infection. 
 
3.8 Sequences of Proteins Used in this Work 
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Evaluation of Sequence Variability in HIV-1  




 In this work, the protein engineering design and initial analysis was done by both Rachel 
Tennyson and myself, as well as cloning and protein purification. I carried out the library design, 
execution, and analysis experiments. Terumasa Ikeda at the University of Minnesota analyzed all 





 The large size, diverse structures, and molecular complexity found in proteins often 
generates surfaces that potently and selectively bind to therapeutically-relevant targets that 
challenge—or evade—small-molecules, including protein-protein interactions (PPIs).[1] 
Additionally, the discovery of protein binders, through laboratory evolution, is often higher-
throughput and simpler than the analogous small-molecule centered discovery process.[2] A 
number of therapeutically significant PPIs feature a cleft that is shape-complementary to an 
exposed α-helix. Given this, the inhibition of PPIs that feature a helix and helix-binding cleft at 
the interface, has been the focus of many therapeutic discovery efforts.[3-15] 
                                                          
1
 Reprinted with permission from: 
Tennyson, R.L.*, Walker, S.N.*, Ikeda, T., Harris, R.S., McNaughton, B.R., Evaluation of Sequence Variability in 
HIV-1 gp41 C-peptide Helix-Grafted Proteins, Bioorganic & Medicinal Chemistry, 2017, 26, 1220 
*Both authors contributed equally 
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 In the previous chapters I described a new approach to folded helix display that relies on 
protein engineering.[16, 17] A stable scaffold protein displaying a helix, which contains at least 
one solvent-exposed face, serves as a generic foundation which can be designed to mimic, or 
extend, any desired helical interface. We term this method ‘helix-grafted display’. In developing a 
general scaffold for helix-grafted display, we sought to identify a protein fold that presents a 
properly folded α-helix in such a way as to permit direct receptor access to one helical face. Ideally, 
the scaffold would be stable, express well as a soluble protein in E. coli, and tolerate multiple 
mutations and/or extension of the helix. Our initial scaffold search identified Pleckstrin Homology 
(PH) domains as suitable starting points. From this work, we identified ELMO, a PH domain 
amenable to helix-grafting (Figure 4.1A).[16] 
We have used helix-grafted display to engineer proteins capable of suppressing HIV-1 
entry.[16] This therapeutic activity is the result of inhibiting an intramolecular PPI between HIV-
1 gp41 C-peptides (α-helix) and a trimer of HIV-1 gp41 N-peptides, which contain C-peptide α-
helix-binding clefts. This PPI generates a ‘trimer-of-hairpin’ assembly that brings HIV and 
mammalian cell membranes into close proximity, leading to membrane fusion and HIV-1 
entry.[18, 19] Helix-grafted proteins presenting a C-peptide surrogate bind pre-fusogenic gp41 N-
peptide trimer, leading to suppression of gp41 fusogenic assembly. 
Cpep-ELMO consists of the ELMO scaffold (with a truncated N-terminal helix) and a 
genetic fusion between the N-terminal ELMO helix and gp41 C-peptide (Figure 4.1B). Cpep-
ELMO binds tightly to gp41 5-helix (KD ~ 90 nM) and suppresses entry of HIV-1 into Cluster of 
Differentiation 4 (CD4) positive human cells.[16] In contrast to its peptide counterpart (the FDA 
approved peptide drug Fuzeon™, or Enfuvirtide), Cpep-ELMO is stable in human serum for 
greater than 12 hours.[20-22] 
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During the course of these earlier studies, we questioned whether or not the gp41 C-peptide 
helix could be evolved for improved function, within the context of helix-grafted display. We 
reasoned that mutation and optimization of solvent-exposed residues on the grafted C-peptide helix 
could result in improved N-peptide trimer recognition, improved expression, and/or improved 
stability of the helix-grafted protein. Additionally, we reasoned that mutating solvent exposed C-
peptide residues, and evaluating this protein library for target affinity, would provide valuable 
information on the relative role each mutated C-peptide residue plays in gp41 N-peptide trimer 
recognition, and the capacity for variation within this helix. With this in mind, we set out to create 
a Cpep-ELMO library, with randomized solvent-exposed residues in the grafted helix, and use 
yeast display to evaluate this helix-grafted display protein library for N-peptide trimer recognition. 
 
 
4.2 Yeast display evolution of a Cpep-ELMO helix-grafted display protein library  
 In the previous chapter, we had first demonstrated that we could graft a portion of gp41 C-
peptide onto ELMO, to generate a new protein that reliably replicates C-peptide display and 
suppresses HIV-1 entry.[16] We next sought to evaluate sequence variability in the grafted helix. 
Figure 4.1 (A) Protein scaffold truncated ELMO (grey, PDB: 2VSZ) with N- and C-terminal 
solvent-exposed helices previously found to be an ideal candidate for grafting the helical ligand 
gp41 Cpeptide (density blue, PDB: 1AIK). (B) Helix-grafted display technology: a 
therapeutically-relevant helix (HIV gp41 C-peptide) is grafted onto N-terminal solvent exposed 




Five positions on Cpep-ELMO (Figure 4.2A) that bury into the C-peptide helix-binding cleft of 
N-peptide trimer (wild-type sequence WWIYI) were randomized by saturation mutagenesis. In 
particular, the tryptophan residues (labeled residues 1 and 2 in Figure 4.2A) we selected to 
randomize are buried in a deep (and conserved) hydrophobic pocket[18]; their deletion has been 
reported to significantly reduce affinity[23]. Thus, these mutations, in a sense, serve as a control 
for amino acid evolution (‘hits’ should regain those tryptophan residues). 
The ~3.2 million-member Cpep-ELMO derived protein library was displayed on yeast, and 
tightest binders were selected by cell sorting. Specifically, the yeast display library was made to 
express Cpep-ELMO derived library members that contain a C-terminal cMyc tag. Following 
expression of our displayed library, yeast was concomitantly incubated with a FITC-labelled anti-
cMyc antibody to confirm expression and display of our proteins and biotinylated gp41 5-helix.[7, 
24] 5-helix is a previously reported protein that covalently tethers five of the six subunits within 
the gp41 trimer-of-hairpins so that when folded, it features the gp41 coiled-coil with two of its 
binding sites already occupied, and just a single exposed interface. This reduces the recognition 
event to a simple 1:1 interaction, simplifying the analysis. Following a brief washing step, 
streptavidin-phycoerythrin conjugate (SA-PE) was incubated with the complex. Thus, yeast 
displaying biotin, by virtue of a surface protein/5-helix interaction, will be bound by SA-PE. Yeast 
were then analyzed by flow cytometry and sorted for the highest FITC fluorescence intensity 
(which comments on display efficiency) and PE red pigment intensity (which comments on 5-
helix binding efficiency, summarized in Figure 4.2B). Yeast that display tightest affinity proteins 
were enriched by flow cytometry over the course of two rounds of screening against 500 nM or 
100 nM biotinylated 5-helix, respectively (Figure 4.2C). 
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From our flow cytometry experiments, we identified eleven unique sequences that retain 
affinity for 5-helix in our yeast display screen. The established preference for tryptophan at 
positions W1 and W2 was faithfully replicated, suggesting that the method is sensitive to tightest 
receptor affinity. Meanwhile, while hydrophobic residues were often selected for, the other 
positions interrogated in this study are reasonably amenable to mutation, supporting the idea that 
variation within certain residues on the binding interface is permitted (Figure 4.2D). We next 
evaluated the effect helix mutations have on structure, expression, stability, function (5-helix 





Figure 4.2 (A) Library design for Cpep-ELMO helix-grafted display library. Residues labeled 
with wildtype sequence, and highlighted as rainbow spheres, were mutated to all possible 20 
proteinogenic amino acids, generating a ~3.2 million-member protein library. (B) Flow 
cytometry enrichment scheme to identify novel Cpep-ELMO helix-grafted proteins that bind to 
gp41 5-helix. (C) Flow cytometry data from yeast display library screening (sort 1: left; sort 2: 
right). Yeast selected in round 1 and round 2, representing 0.4% and 1% of the total population, 
respectively, are within dashed boxed. (D) Sequence logo generated from 11 unique Cpep-
ELMO derived mutants enriched after two rounds of yeast display screening. 
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4.3 Evolved Cpep-ELMO mutants retain affinity for HIV-1 gp415-helix 
  Given the findings from our yeast display screening, whether or not solvent exposed 
residues on the gp41 C-peptide helix are amenable to mutation is no longer in question. What 
remained a question, however, was what effect these mutations had on the affinity for gp41 5-
helix. We assessed binding between Cpep-ELMO mutants and gp41 5-helix by in vitro ELISA. 
 Biotinylated gp41 5-helix (Supplemental Figure 6.3A) was first immobilized onto 
commercially available streptavidin coated plates, which were then washed to remove unbound 
protein. Enriched mutants (Cpep1-ELMO – Cpep11-ELMO) containing a C-terminal FLAG tag 
were separately incubated with immobilized 5-helix and a commercially available anti-FLAG 
antibody conjugated to HRP. Binding was analyzed by measuring absorbance, following 
incubation with TMB One™ substrate. Of the initial eleven hits, five proteins (Cpep1, 3, 4, 5, 8-
ELMO) compared favorably to Cpep-ELMO and warranted further investigation (Figure 4.3A). 
Amino acid composition of Cpep-ELMO, and our evolved proteins at mutated positions is shown 
in Figure 4.3B. 
 
 
Figure 4.3 (A) ELISA data showing binding between immobilized gp41 5-helix and Cpep-
ELMO, or mutants described in this work. Error bars represent the standard error of the mean 
from three replicate experiments. (B) Sequence of Cpep-ELMO, and mutants selected for by 
yeast display that compare favorably in ELISA experiment to Cpep-ELMO (Cpep1-ELMO, 
Cpep3-ELMO, Cpep4-ELMO, Cpep5-ELMO, and Cpep8-ELMO). 
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4.4 Evolved Cpep-ELMO proteins are structured, stable, and in some cases, express more 
robustly in E. coli 
 Given the findings from our yeast display screening and ELISA experiments, the solvent-
exposed residues on the gp41 C-peptide helix were found to be amenable to mutation and retain 
function of binding the target gp41 helical bundle. What remained to answer, however, was what 
effect these mutations had on the larger protein structure. We began by comparing protein 
expression levels of mutants to our starting protein (Cpep-ELMO). In addition to selecting for 
improved target affinity, display-based methods often select for proteins with improved stability 
and expression[25]. We expressed five of the tightest binding Cpep-ELMO mutants in E. coli as 
N-terminal His6x fusions, and purified them by nickel-NTA chromatography. Levels of purified 
proteins were then measured as mg/L of culture with spectroscopy (nanodrop analysis). As shown 
in Figure 4.4A, all but one of our evolved proteins expressed at higher levels, compared to Cpep-
ELMO. While Cpep-ELMO expressed modestly in E. coli (~2.5 mg/L), our best performing 
mutants, Cpep3-ELMO and Cpep4-ELMO, expressed more than two-fold higher (Figure 4.4A and 
Supplemental Figure 6.3B). 
 In addition to expressing better in E. coli, evolved mutants retain structural features 
associated with our starting protein (Figure 4.4B) as assessed by circular dichroism (CD). This 
makes sense: high efficiency yeast display requires proper protein folding and shuttling to the cell 
surface. Our yeast display screen concomitantly selects for robust expression, protein stability, and 
high affinity for gp41 N-peptide. 
 Having established that mutations selected for in our yeast display experiment do not 
appreciably alter protein structure, we next evaluated the effect yeast display evolution had on 
protein stability. Relative stabilities of Cpep-ELMO, and evolved mutants were measured by 
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thermally denaturing (0 °C – 90 °C) each protein and measuring helicity by CD at 222 nm (Figure 
4.4C). Mutated proteins unfolded within the range 44–57°C, which is not dramatically lower than 
what is the observed melting temperature for Cpep-ELMO (57 °C). Collectively, these findings 
show that proteins evolved in our yeast display screen not only retained affinity for gp41 5-helix, 
but these proteins express—sometimes more robustly—as soluble proteins in E. coli, and these 
proteins retain their structure and stability. 
  
 
4.5 Evolved Cpep-ELMO mutants suppress HIV infection in a live virus assay 
 Having demonstrated that some of our evolved C-peptide ELMO helix-grafted display 
proteins express better than Cpep-ELMO, retain helical structure, and bind to gp41 5-helix in vitro, 
we next measured their ability to suppress HIV infection using a live virus assay we have 
previously reported[16, 26]. In this method, HIV IIIB is administered to CD4+ mammalian cells 
stably integrated with a plasmid that encodes the HIV-1 long-terminal repeat (LTR) upstream of 
green fluorescent protein. Since HIV-1 Tat/TAR-dependent transcription ultimately leads to the 
expression of GFP, we will be able to see if HIV-1 infects these cells. The number of cells that 
express GFP correlates to the number of cells infected with the virus and can thus be measured via 
Figure 4.4 (A) Expression levels, in E. coli, for our starting helix-grafted display protein (Cpep-
ELMO) and mutants generated from our yeast display screen (Cpep1-ELMO, Cpep3-ELMO, 
Cpep4-ELMO, Cpep5-ELMO, and Cpep8-ELMO). (B) Circular dichroism spectra for Cpep-
ELISA and mutants described in this work showing most mutants retained similar secondary 
structural composition. (C) Melting data for Cpep-ELMO and mutants described in this work 
showing mutants retaining protein thermal stability. 
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flow cytometry. As seen in Figure 4.5, all but one of the evolved helix-grafted display proteins 
(Cpep8-ELMO) inhibit HIV-1 entry better than the original helix-grafted display protein, Cpep-
ELMO. A number of our mutated proteins have dramatically improved Half-Maximal Inhibitory 
Concentration (IC50) values for suppression of HIV-1 entry (IC50: Cpep1-ELMO: 0.43 μM; Cpep3-
ELMO: 0.31 μM; Cpep4-ELMO: 0.77 μM; Cpep5-ELMO: 0.19 μM. In contrast, the IC50 of our 




 4.6 Conclusion 
 Many disease-relevant protein-protein interactions (PPIs) utilize interfaces that involve an 
α-helix and helix-binding groove. In order to disrupt these PPIs, researchers have developed 
various techniques to stabilize helical display of side chains within a peptide or peptide mimetic. 
While these techniques, such as peptide ‘stapling’, ‘hydrogen-bond surrogate’ engineering, and 
helical ‘foldamers’ represent important sectors of biomimetic research, and are important reagents 
Figure 4.5 Normalized suppression of HIV-1 entry in CD4-positive cells in a live virus assay 
by Cpep-ELMO and derivatives. Each data point reports HIV-1 infectivity relative to the peptide 
hydrating buffer treated control (mean +/− SEM from 3 replicates; error bars not shown are 
smaller than the data points). 
82 
 
for inhibiting disease-relevant PPI’s that feature a helix-binding groove, their synthesis and 
purification can be expensive and laborious. Researchers have also described ‘minimal proteins’ 
with an evolved helix (for tailored recognition); however, these polypeptides do not express as a 
folded protein in E. coli and must be prepared by solid-phase peptide synthesis, which is also 
laborious and expensive. 
 In the previous chapters I discussed ‘helix-grafted display’, a potentially general solution 
for displaying a folded therapeutically-relevant helix on a protein scaffold. In Chapters 2 and 3, 
we showed that a Pleckstrin Homology (PH) domain can be resourced as a helix-grafted display 
scaffold, wherein a solvent-exposed helix serves in the wild-type protein serves as a generic canvas 
upon which to paint, or extend, any desired helical interface. My research has focused on the 
development of new proteins that display HIV-1 gp41 C-peptide, an established therapeutic 
reagent. We showed that Cpep-ELMO, an engineered protein that displays gp41 C-peptide as a 
fusion to the N-terminal helix of the ELMO PH domain, binds to gp41 5-helix, which mimics the 
pre-fusogenic state of gp41 and serves as a therapeutically-relevant target. Cpep-ELMO potently 
binds to gp41 5-helix (KD ~ 90 nM) and suppresses HIV entry into CD4-positive cells, in a 
concentration-dependent manner. 
 In this work, we sought to optimize properties of Cpep-ELMO mutants by mutating five 
C-peptide binding face residues to all possible proteinogenic amino acids and selecting for efficient 
display on yeast (which relates to stability) and 5-helix recognition. As a result of this screen, we 
reasoned that we could not only improve recognition, but also assess the variability of sequences 
within the solvent-exposed binding face of C-peptide in our helix-grafted protein. After screening 
a ~3.2 million-member Cpep-ELMO derived library, we found that two neighboring tryptophan 
residues (labeled W1 and W2 in this work, Figure 4.2A) are enriched for, supporting previous 
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findings detailing their importance in gp41 5-helix recognition. Thus, their enrichment 
demonstrated the ability of our yeast display screen to enrich for residues necessary for 5-helix 
recognition. Other residues, however, (labeled I3, Y4, and I5 in this work, Figure 4.2A) exhibit 
sequence variability. While hydrophobic residues are generally selected for at these positions, no 
single residue emerged as absolutely necessary, or even particularly favored. Using eleven proteins 
(Cpep1-ELMO–Cpep11-ELMO) enriched in our screen, we measured their expression in E. coli, 
structure, and stability. We also measured the ability of these proteins to recognize gp41 5-helix 
and suppress HIV entry using a live virus assay. These characteristics and activities were compared 
to our starting protein, Cpep-ELMO. 
 Satisfyingly, 5 of the 11 favor comparably to Cpep-ELMO when it comes to 5-helix 
recognition; all 5 of these proteins exhibit CD spectra that indicates retention of helical structure; 
all express as soluble proteins in E. coli, and in some cases, expression levels are improved, in 
comparison to the starting protein. Finally, 4 of our evolved proteins (Cpep1-ELMO; Cpep3-
ELMO; Cpep4-ELMO; Cpep5-ELMO) suppress HIV-1 entry better than our starting helix-grafted 
protein (Cpep-ELMO). This work shows that solvent-exposed residues on C-peptide are 
amendable to mutation, and that their mutation can generate new proteins with improved properties 
and therapeutic activity.[27] 
 
 4.7 Methods 
Protein Expression and Purification  
Genes were cloned into pET using restriction enzymes BamHI and KpnI, downstream of a His6x 
tag and transformed into BL21s (DE3). Cells were grown in 1 L 2XYT cultures containing 100 
g/mL carbenicillin at 37 °C to OD600 =0.5 - 0.8 and induced with 1 M IPTG at 25 °C overnight. 
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Cells were then collected by centrifugation, resuspended in PBS buffer (20 mM Na2HPO4 pH 7.4, 
100 mM NaCl) and stored at -20 °C. Frozen pellets were thawed and sonicated with 1 second 
pulses for 3 minutes. The lysate was cleared by centrifugation (8,000 rpm 10 min.) and the 
supernatant was mixed with 1 mL of Ni-NTA agarose resin for 30 min at 4 °C. The resin was 
collected by centrifugation (4300 rpm, 10 min.). The resin was sequentially washed with 30 mL 
of PBS buffer containing 20 mM imidazole, 50 mL buffer containing 50 mM imidazole, and 15 
mL buffer containing 75 mM imidazole. The protein was then eluted with 4 mL PBS buffer 
containing 400 mM imidazole. The proteins were dialyzed against PBS buffer and analyzed for 
purity by SDS-PAGE. Purified protein concentrations were quantified using Beer’s Law at an 
absorbance of 280 nm, following standard practice.1 Protein expression was calculated as a 
measure of eluted protein yield in mg/L of induced E. coli culture. 
Resolubilization of 5helix Inclusion Bodies  
5helix-His6x was cloned into a modified pETDuet-1 vector using restriction enzymes NdeI and 
KpnI and transformed into BL21s (DE3). Cells were induced to express 5helix-His6x and lysed as 
described above. The lysate was cleared by centrifugation (8,000 rpm, 20 min.) and the supernatant 
discarded. The pellet was washed twice with PBS buffer containing 0.5 % Triton® X-100 and 
once with PBS buffer. The pellet was resuspended in urea buffer (PBS buffer with 8 M urea and 
10 mM imidazole) to resolubilize the inclusion bodies and cleared by centrifugation (8,000 rpm, 
30 min.) The supernatant was mixed with 1 mL of Ni-NTA agarose resin for 1 hour at 4 °C. The 
resin was collected by centrifugation (4,300 rpm, 4 min.). The resin was washed with 50 mL of 
urea buffer and eluted with 40 mL of urea elution buffer (PBS buffer with 6 M urea and 100 mM 
imidazole) into 460 mL PBS buffer by gravity elution while stirring to refold the protein. The 500 
mL elution was run through a column containing 1 mL of Ni-NTA agarose resin and eluted with 
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5 mL PBS buffer containing 400 mM imidazole. The protein was dialyzed against PBS buffer and 
analyzed for purity by SDS-PAGE. Refolding analysis was conducted by CD. Purified proteins 
were quantified using Beer’s Law at an absorbance of 280 nm.  Protein expression was calculated 
as a measure of eluted protein yield in mg/L of induced E. coli culture.  
Circular Dichroism  
Proteins were purified as described above. Separately, each protein was diluted to 3-10 μM in PBS 
buffer. Wavelength data are the average of three scans from 250 nm to 200 nm in 1 nm steps at 25 
°C. Thermal denaturation experiments at 222 nm were run from 0 to 90 °C in two-degree steps at 
a two-degree/minute rate of increase with one-minute equilibration and data averaging at each 
temperature. Tm values were obtained from minima of the first derivative of θ versus 1/T plots.  
Biotinylation 
5helix-His6x was cloned into a pET vector containing an upstream Avitag™ 
(GLNDIFEAQKIEWHE)-GGSGGSGGT linker using restriction enzymes KpnI and PacI. The 
protein was resolublized from inclusion bodies as described above in PBS buffer. His6x-BirA was 
cloned into pET using restriction enzymes NcoI and KpnI and purified as described above in 
Phosphate buffer. 300 L of Avitagged™ 5-Helix-His6 protein at 38 M was incubated with 6 L 
of His6-BirA at 1 mg/mL using Avidity® BirA biotin-protein ligase standard reaction kit at 30°C 
for 40 min. Biotinylation was confirmed by Agilent 6220 TOF LC-MS.  
In vitro ELISA 
Helix-grafted Cpep-ELMO proteins were cloned into a pET vector upstream of a C-terminal 
His6x-GS-FLAG tag (DYKDDDDK) using restriction enzymes NheI and BamHI. Proteins were 
purified as described above in PBS buffer. The biotinylated AvitaggedTM 5-helix-His6 (biotin-
5helix) was prepared as described above in PBS buffer and diluted to 10 g/mL. Pierce® 
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Streptavidin coated clear 96-well plates with a binding capacity of 5 pmol were pre-blocked with 
200 L of wash buffer (PBS buffer, 0.5 mg/mL BSA, 0.1% tween® 20) for 1 hour. Biotin-5helix 
was immobilized on the streptavidin-coated plates by incubating 100 L of diluted protein for 1 
hour at room temperature, followed by 4x 200 L washes (5 min). 100 L of Cpep-ELMO proteins 
were incubated at a concentration of 75 nM for 1 hour, followed by 4x 200 L 4°C washes (5 
min). 100 L of a 1:10,000 dilution of HRP-conjugated mouse anti-DDDDK antibody in 
Odyssey® Blocking Buffer was incubated for 1 hour at room temperature, followed by 4x 200 L 
4°C washes (5 min). Color was developed using TMB-One substrate and absorbance was 
measured at 655 nm on a SynergyMx Microplate Reader. 
Infectivity Assay 
All proteins were shipped on ice in a 20% glycerol-PBS stock. HEK293T cells were maintained 
in DMEM supplemented with 10% fetal bovine serum (FBS) and 0.5% penicillin/streptomycin 
(P/S). CEM-GFP cells were cultured in RPMI with 10% FBS and 0.5% P/S. The procedure was 
virtually identical to a previously published variant.  The HIV-1 IIIB C200 proviral expression 
construct has been described previously.  Viruses were produced by transfection of 3.0 µg of Vif-
proficient proviral expression construct into 293T cells (3.0x106) using TransIT®-LT1 reagent. 48 
hr later, virus-containing supernatants were filtered by 0.45 µm filters and used to infect into 
2.5x104 CEM-GFP cells with varying concentration of inhibitors. Infectivity (GFP+ cells) was 
measured by flow cytometry at 2 days post-infection. 
Protein Library Preparation  
EBY100 yeast (trp-, leu-, with the Aga1p gene stably integrated) and the pCTCON2 plasmid were 
generously provided by the Wittrup lab (MIT). The gene encoding Cpep-ELMO was amplified by 
PCR and cloned into pCTCON2 in-frame with Aga2, an N-terminal HA-tag, and a C-terminal myc 
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tag, using the restriction enzymes NheI and BamHI. When analyzed for display only, Cpep-ELMO 
displayed efficiently on EBY100 cells (~60-85 %, data not shown). Next, the Cpep-ELMO library 
was created by amplifying the Cpep-ELMO gene with 5 sites in the N-terminal α-helical region 
(Trp1, Trp4, Ile8, Tyr11, and Ile15) substituted with NNK codons. Using restriction enzymes NheI 
and BamHI, the library amplicon was digested and inserted into a digested pCTCON2 plasmid 
previously containing an insert with several successive stop codons to prevent false positive 
screening (nonsense pCTCON2). The resulting DNA plasmid was used as a template for a second 
PCR with homologous recombination primers, Fwd: (5′-CTC TGG TGG AGG GCG TAG CGG 
AGG CGG AGG GTC GGC TAG C-3′) and Rev: (5′-CGA GCT ATT ACA AGT CCT CTT CAG 
AAA TCA GCT TTT GTT CGG ATC C-3′), which are designed to create an insert with ~40 base 
pairs of overlap with the pCTCON2 vector. The resulting amplicon, containing the randomized 
sequences, was then cloned into pCTcon2 using homologous recombination in EBY100 yeast. 
Approximately 1 µg of nonsense pCTCON2 vector cut with BamHI and NheI was mixed with ~3 
µg of the amplified library, ethanol precipitated, and transformed via electroporation into 50 µL 
of electrocompetent EBY100 using 2 mm cuvettes. 10 of these electroporations were performed 
and each was immediately rescued with 2 mL pre-warmed YPD and combined for 2 hours at 30 
°C. After rescue, yeast were centrifuged at 2,500 xg for 1 minute, and supernatant YPD was 
removed. Yeast were resuspended in 1 mL fresh SD-CAA (5.4 g/L Na2HPO4, 8.6 g/L NaH2PO4 • 
H2O, 20 g/L dextrose, 6.7 g/L yeast nitrogen base lacking amino acids, 5 g/L casamino acids, 200 
kU/L penicillin, 0.1 g/L streptomycin). A small portion was plated by serial dilution onto SD-CAA 
plates, and incubated at 30 °C for 3 days in order to determine the transformation efficiency. The 




recombination transformation was determined to be 1 x 107 – 1.63 x 107 using the equation below. 
transformation efficiency = (# colonies x Vol quenched)/(dilution x Vol plated). 
Yeast Display Screening 
After 2-3 days of growth in SD-CAA, the library was sub-cultured in SD-CAA at an initial density 
of 0.5 x 107 cells/mL and grown to a density of 2.0 x 107 cells/mL. Yeast were subsequently sub-
cultured in SG-CAA (Galactose containing induction media) to a concentration of 1.0 x 107 
cells/mL and grown for 1-2 days shaking at 250 RPM at a temperature of 25 °C. For each round 
of screening, approximately 108 cells were pelleted and washed with 1 mL of 4 °C PBS-BSA 
(Corning CellGro PBS 1x with 1 g/L BSA filter sterilized). Yeast were subsequently incubated 
with biotin-5helix at the concentrations given in the table below and a 1:250 dilution of FITC-
conjugated anti-myc antibody at room temperature. After incubation, the yeast cells were 
incubated on ice for 5 minutes, pelleted at 12,000 xg for 30 seconds 4 °C and washed with 1 mL 
ice-cold PBS-BSA. The yeast was pelleted again and incubated with a 1:100 dilution of SA-PE in 
PBS-BSA on ice for 1 hour. After incubation, a final wash with ice-cold PBS-BSA was performed, 
and yeast positive for both FITC (display) and R-Phycoerythrin (5helix-binding) were sorted into 
7 mL of SD-CAA media using a MoFlo Flow Cytometer (Beckman-Coulter). Sorted yeast were 
transferred to 50 mL of pre-warmed SD-CAA and incubated at 30 °C for 3 days shaking at 250 
RPM. Additionally, plasmid DNA was recovered from the sorted library using a Zymoprep yeast 
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Evolved Biologics Designed for Monthly Administration Potently 




 In this work, the protein engineering design and initial analysis was done by both Rachel 
Tennyson and myself, as well as cloning and protein purification. I carried out the library design, 
execution, and analysis experiments. Terumasa Ikeda at the University of Minnesota analyzed all 





 Individuals at high risk for HIV-1 infection often take pre-exposure prophylaxis (PrEP), a 
cocktail consisting of Emtricitabine and Tenofovir (both reverse transcriptase inhibitors).[1] For 
patients already infected with HIV-1, therapeutics are available that act on a number of proteins 
necessary for HIV-1 proliferation. For example, the principal components of combination 
antiretroviral therapy (cART) are typically inhibitors of viral protease and reverse transcriptase 
enzymes.[2] Both PrEP and cART require daily administration due to the relatively short in vivo 
lifetime of these small-molecule drugs.[1, 2] Given the stigma associated with HIV infection, there 
is a significant psychological barrier to obtaining, storing, and taking—on a daily basis—HIV 
antiretroviral prophylaxis and therapeutics. Since PrEP and cART do not inhibit HIV-1 entry, even 
                                                          
1
 Reprinted with permission from: 
Ikeda, T.*, Tennyson, R.L.*, Walker, S.N.*, Harris, R.S., McNaughton, B.R., Evolved Biologics Designed for 
Monthly Administration Potently Inhibit Entry of Enfuvirtide-Resistant HIV-1, ACS Infectious Disease, 2019.  
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miniscule levels of replication-competent viral genome integration by intracellular HIV-1 can lead 
to the formation of latent viral reservoirs, which make a cure virtually impossible. Since inhibition 
of virus entry, by definition, stops viral genome integration, entry inhibition may be preferred to 
protect against HIV-1 infection and the formation of latent viral reservoirs. 
 HIV infection is initiated by binding between HIV gp120 and the cluster of differentiation 
4 (CD4) receptor on immune cells, such as T helper cells, monocytes, macrophages, and dendritic 
cells.[3, 4] This recognition event is followed by a conformational change in HIV gp120, which 
exposes another HIV protein – viral glycoprotein gp41. The C-terminus of gp41 inserts into the 
HIV membrane, while the N-terminus inserts into the membrane of the engaged immune cell. 
Physical entry of the viral contents into the bound immune cell requires conformational collapse 
of prefusogenic N-peptide and C-peptide trimers into a “trimer-of-hairpins” assembly that 
promotes membrane fusion – a mandatory step for infection.[5] 
 Only one FDA approved HIV entry inhibitor (Enfuvirtide) targets gp41.[6, 7] Enfuvirtide 
is a 36-residue synthetic peptide that binds pre-fusogenic gp41 N-peptide trimer, inhibiting 
formation of the “trimer-of-hairpins” assembly required for viral membrane fusion and HIV 
infection of a host immune cell. Enfuvirtide is costly to synthesize, has poor solubility and 
bioavailability, is sensitive to serum and interstitial proteases (in vivo half-life is approximately 4 
hours) and thus requires daily parenteral administration.[8] Long-lasting Enfuvirtide conjugates 
have been reported[9]; however, they require additional chemical synthesis and purification. Since 
Enfuvirtide is a single peptide, mutation of HIV gp41 can lead to Enfuvirtide-resistance.[10, 11] 
Researchers have reported D-peptides[12], mixed α/β peptides[13], and longer helical scaffolds 




We have reported a technique called ‘helix-grafted display’: a protein engineering-based 
solution to generate biologics that target therapeutically-relevant helix-binding clefts. While likely 
applicable to the myriad of disease-relevant protein-protein interactions that involve a helix and 
complementary surface, our studies have focused on targeting the prefusogenic HIV-1 gp41 N-
peptide trimer.[15, 16] We have focused on Pleckstrin Homology domains (PH domains) as a 
helix-grafted display scaffold, since these proteins are generally stable, express in E. coli (a 
common bioproduction host), and contain a solvent-exposed helix.[17-19] First, specific helix 
residues are mutated to mimic gp41 C-peptide helix. Once the native helix is utilized, the 
remaining gp41 C-peptide helix is then genetically fused. The resulting protein mimics a folded 
gp41-C-peptide helix. We have shown that GLUE-Cpep[16], and a second-generation helix-
grafted protein, Cpep-ELMO (C26-ELMO)[15], bind to gp41 ‘5-helix’, which researchers, 
including our lab, have used as a surrogate for pre-fusogenic N-peptide trimer.[20] 5-helix is a 
single polypeptide that contains three copies of gp41 N-peptide and two copies of C-peptide. This 
architecture presents one vacant C-peptide binding site, thus simplifying the interaction to a 1:1 
complex between 5-helix and C-peptide (or a C-peptide helix-grafted display protein). While 
Cpep-ELMO binds to 5-helix, it exhibits modest inhibition of HIV entry (IC50 >1 μM). Evolving 
Cpep-ELMO through saturation mutagenesis and yeast display screening has improved the 
effective inhibition to an IC50 of ~190 nM (Cpep5-ELMO), but the limitations of an N-terminal 
graft decrease serum stability compared to C-terminal graft GLUE-Cpep and limit helical 
elongation.[21] On the basis of these findings, we set out to optimize the scaffold and evolve the 





5.2 Helix-grafted Sac7d (Sac7d-Cpep) potently binds 5-helix in E. coli cell lysate. 
 Previous studies suggested a relationship between the size of the helix-grafted display 
scaffold and HIV-1 entry inhibition: smaller scaffolds are more effective.[15] We therefore set our 
sights on a miniature (<10 kDa) PH domain (or structurally related protein) that expresses well in 
E. coli and is amenable to the extensive helix mutagenesis required for grafting and sequence 
optimization. Analysis of the Protein Data Bank (PDB), and literature, revealed Sac7d – a 7 kDa 
protein originating from the hyperthermophilic archaeon Sulfolobus (PDB: 2XIW).[22] We 
engineered this protein using helix-grafted display to function as a C-peptide mimic and analyzed 
the minimalist protein for structural and functional fidelity. Helix-grafted Sac7d (Figure 5.2A) 
expresses as a soluble protein in E. coli (Supplemental Figure 6.4A), and circular dichroism 
experiments show that it maintains structural features found in the wild-type protein with extended 
helical character (Figure 5.2B).  
 When 5-helix-His6 is expressed in E. coli in the absence of a binding partner, it expresses 
as an inclusion body and must be refolded. This is likely due to aggregation cause by the solvent-
exposed hydrophobic C-peptide binding site. However, when 5-helix-His6 is appropriately bound 
by another protein, effectively filling the hydrophobic C-peptide binding site, both proteins can be 
co-purified from E. coli lysate with nickel-NTA resin. When 5-helix-His6 and Sac7d are co-
expressed in E. coli, we observe no purified protein following incubation with nickel-NTA resin 
and elution with imidazole (Figure 5.2C, lane 1), indicating that Sac7d doesn’t appreciably bind 
5-helix-His6. However, when 5-helix-His6 is expressed concomitantly with Sac7d-Cpep, both 
proteins readily co-purify following incubation with nickel-NTA agarose beads and elution with 
imidazole (Figure 5.2C, lane 2), indicating that the two proteins form a tight association in a 
complex biological solution that contains thousands of alternative proteins, and a virtual sea of 
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nucleic acids and other biological molecules. Formation of the desired complex was further 
assessed by in cellulo ELISA, which indicates binding between Sac7d-Cpep and immobilized 5-
helix, but no appreciable affinity between Sac7d and 5-helix (Figure 5.2D). 
 
 
5.3 Sac7d-Cpep potently inhibits HIV entry in a live virus assay. 
  To measure inhibition of HIV entry, or lack thereof, we previously used a live-virus assay 
that links HIV infection of CD4-positive T cells to GFP fluorescence.[15, 23] In this method, HIV 
IIIB is administered to CD4+ T cells stably integrated with a plasmid that encodes the HIV-1 long-
terminal repeat (LTR) upstream of green fluorescent protein (GFP).[24] Since HIV Tat/TAR-
dependent transcription ultimately leads to the expression of GFP, cells that express GFP correlates 
Figure 5.2 (A) Helix-grafted display of gp41 C-peptide (density blue) onto the solvent-exposed 
helix of a PH-like domain scaffold, Sac7d (grey). Grafted residues are shown as density blue 
spheres. (B) Circular dichroism data for Sac7d and Sac7d-Cpep showing retention of structural 
elements post-grafting. (C) Sac7d-Cpep binds 5-helix in E. coli. Lane 1: E. coli cell lysate 
containing Sac7d and 5-helix-His6. Sac7d does not co-purify with 5-helix-His6 on nickel-NTA 
agarose. Lane 2: E. coli cell lysate with Sac7d-Cpep and 5-helix-His6. Sac7d-Cpep co-purifies 
with 5-helix-His6 on nickel-NTA agarose. (D) In cellulo ELISA showing 5-helix binding to helix-
grafted Sac7d-Cpep and Cpeptide in a complex cellular environment and no binding of the 
wildtype Sac7d scaffold to 5-helix. 
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to the number of infected cells and can thus be measured via flow cytometry. Sac7d does not inhibit 
HIV entry (Figure 5.3). In contrast, Sac7d-Cpep potently inhibits HIV entry (IC50 ~1.9-12.4 nM , 
Table 5.7, entry 1), and compares favorably to Enfuvirtide (IC50 ~0.7-3.5 nM , Table 5.7, entry 5) 
and gp41 C-peptide (IC50 ~1.0-6.7 nM , Table 5.7, entry 4). In addition to Sac7d-Cpep, we prepared 
and evaluated a number of other helix-grafted proteins, in which the helix consists of the 
Enfuvirtide sequence, or C-46, which contains C-peptide and Enfuvirtide (Figure 5.3 and Table 
5.7, entries 2-3). While these proteins express as soluble proteins from E. coli, they are less active 
as HIV entry inhibitors (Sac7d-C46 IC50 ~23.6 nM and Sac7d-Enfuvirtide 39.7 nM). Moreover, 
since Enfuvirtide lacks residues (tryptophans) necessary for 5-helix recognition, this scaffold 
cannot be evolved for improved 5-helix recognition. Given all of this, we focused on Sac7d-Cpep 
as an initial starting point to generate a therapeutic cocktail from the evolution of solvent-exposed 





Figure 5.3 Sac7d-Cpep potently inhibits HIV entry in a live virus assay (IC50 ~1.9-12.4 +/- 0.2-
1.3 nM). Error bars represent the standard error of the mean (SEM) for three separate 
experiments. If error bars are not visible, error is smaller than the data point. 
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5.4 First-generation helix evolution provides potent entry inhibitors with dramatically 
improved expression in E. coli. 
 We set out to use protein evolution to identify a cocktail of Sac7d-Cpep based proteins with 
affinity for 5-helix. We envisaged that if evolved forms of Sac7d-Cpep—with sequence diverse 
residues on the solvent-exposed helix face—retain affinity 5-helix, the molecular underpinnings 
of recognition could vary substantially. If true, we reasoned that it would likely be more difficult 
for HIV to rapidly evolve resistance to the polyclonal nature of the ensemble, compared to a single 
molecule like Enfuvirtide. Moreover, we reasoned that evolved proteins could bind viral gp41 in 
a manner that overcomes mutations leading to viral resistance.  
 The first two C-peptide grafted residues on Sac7d-Cpep are both tryptophans (WW, white 
spheres, Figure 5.4A). Multiple labs, including our own, have shown that these two tryptophan 
residues are critical to binding a complex between C-peptide and gp41 5-helix.[21] Thus, we 
avoided mutation of these critical residues. In the first-generation of helix optimization, we 
mutated five residues downstream of the tryptophans on the solvent-exposed face of the helix 
(EIYTI, light blue spheres, Figure 5.4A) to all proteinogenic amino acids, generating a protein 
library of approximately 3.2 x 106. Yeast were induced to display the Sac7d-Cpep based library, 
equipped with an N-terminal myc tag.[21, 25] Following display, yeast was concomitantly 
incubated with a FITC-labeled anti-myc antibody and biotinylated gp41 5-helix. Following a brief 
washing step, streptavidin-phycoerythrin conjugate (SAV-PE) was added. Thus, yeast featuring 
biotin near their cell surface, by virtue of a surface protein/5-helix interaction, will be bound by 
SA-PE (Figure 5.4B). Following additional washing, yeast were analyzed by flow cytometry, and 
sorted for the highest FITC fluorescence intensity (display efficiency) and PE red pigment intensity 
(5-helix binding efficiency). Yeast displaying tightest affinity proteins were enriched over the 
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course of two rounds of screening against 1 nM or 100 pM biotinylated 5-helix, respectively. In 
both rounds, 10 nM Cpep-ELMO was added as a competitor for 5-helix recognition (Figure 5.4C, 
Supplemental Table 6.4).  
 After two rounds of first-generation optimization we sequenced 30 clones, revealing 14 
unique sequences. The amino acid preference for each randomized position is depicted in Figure 
5.4D. For the first randomized residue (glutamic acid, E, Figure 5.4A), we observe a preference 
for the wild-type residue. Aspartic acid was also observed in selected proteins, suggesting that a 
carboxylic acid side chain is necessary at this position. However, we observe significant 
heterogeneity at the four other residues optimized by yeast display – indicating that multiple 
solutions to potent recognition of 5-helix exist. While the overwhelming majority of the amino 
acids we enriched for are hydrophobic, the steric footprint of these residues varies dramatically. 
 New 5-helix binders were first evaluated by in vitro ELISA (Figure 5.4E) and seven 
proteins were identified as comparing favorably with Sac7d-Cpep (greater than 90 % of ELISA 
signal relative to Sac7d-Cpep). These proteins were next evaluated for their ability to inhibit HIV 
entry. Satisfyingly, all seven proteins inhibit HIV entry virtually identically (Figure 5.4F, Table 
5.7, entry 6-12). To differentiate these proteins, we measured their expression yield in E. coli 
(Figure 5.4G, Supplemental Figure 6.4B). Most dramatically, we observed an 18-fold increase in 
expression of Sac7d-Cpep1.1, compared to Sac7d-Cpep. First-generation residues optimized in 
Sac7d-Cpep1.1 are EAWLL, which vary substantially from the wild-type residues EIYTI. We 
wanted to characterize the improved binding interaction for the evolved C-peptide mimic. 
Although reports of the dissociation constants (KD) vary for the C-peptide/5-helix complex 
depending on the method used to obtain the value, the KD can be compared in each individual 
method to extract fold change from C-peptide mimics to the C-peptide. Using a previously reported 
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method, we utilized yeast display to characterize the KD for complexes involving 5-helix and 
Sac7d-Cpep, Sac7d-Cpep1.1, or C-peptide. The binding interaction to 5-helix exhibited 3-fold 
improvement from C-peptide to Sac7d-Cpep and 7-fold improvement from C-peptide to Sac7d-
Cpep1.1 (Figure 5.4H). On the basis of these collective findings, Sac7d-Cpep1.1 was used as a 






Figure 5.4 (A) Helix optimization strategy. White spheres (tryptophans) remain unaltered 
grafted residues due to the essential nature involved in binding gp41 5-helix. Light blue 
spheres were optimized in generation 1; tan spheres were optimized in generation 2. (B) Yeast 
display optimization schematic. (C) Yeast display data from two rounds of generation 1 
screening. (D) Sequence logo for residues of 14 unique proteins optimized during generation 
1 of yeast display screening. (E) In vitro ELISA data of generation 1 variants relative to Sac7d-
Cpep signal. Dashed line represents 90% cutoff for variants progressing through further 
analysis. (F) Inhibition of HIV entry of Sac7d-Cpep, C-peptide, Enfuvirtude, and generation 1 
optimized proteins. (G) Protein expression of generation 1 evolved proteins in E. coli relative 
to Sac7d-Cpep. (H) Binding affinity for 5-helix recognition was quantified for Cpeptide (82.6 +/- 
8.6 pM), helix-grafted Sac7d-Cpep (27.4 +/- 3.7 pM) and evolved Sac7d-Cpep1.1 (11.4 +/- 2.1 
pM) by displaying each protein or peptide on yeast. Varying concentrations of biotin-5-helix / 
streptavidin-phycoerythrin were incubated with the yeast and the normalized mean 
fluorescence intensity of phycoerythrin was plotted against biotin-5helix concentrations. Error 
bars represent the standard error of the mean (SEM) for three separate experiments. If error 
bars are not visible, error is smaller than the data point. 
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5.5 Second-generation helix evolution delivers a cocktail of potent entry inhibitors. 
 Using Sac7d-Cpep1.1 as a starting point, solvent-exposed residues on the C-terminal 
region of the grafted helix (LISQQ, tan spheres, Figure 5.4A) were randomized and enriched for 
5-helix recognition by yeast display. As before, these five residues were randomized, generating a 
3.2 x 106 protein library and highest affinity binders to 5-helix were enriched by flow cytometry. 
Second-generation helix optimization was conducted over the course of three rounds (4 nM; 200 
pM, or 50 pM biotinylated 5-helix with 1 nM Sac7d-Cpep as competitor) (Figure 5.5A and 
Supplemental Table 6.4).  
 Following the final enrichment round, we sequenced 50 plasmids encoding evolved 
proteins, providing 20 unique protein sequences. We observed high levels of sequence variability 
at positions randomized and optimized in our yeast display screen (Figure 5.5B), suggesting that 
multiple solutions to potent 5-helix recognition exist within this region of the C-peptide helix. 
Affinity for 5-helix recognition was again assessed by in vitro ELISA (Figure 5.5C) and lowest 
affinity binders were triaged (signal less than Sac7d-Cpep). Satisfyingly, despite dramatic 
resurfacing of the solvent-exposed face of C-peptide, many proteins evolved in second-generation 
helix optimization expressed more efficiently in E. coli, compared to Sac7d-Cpep. The evolved 
proteins with low expression in E. coli were also eliminated (Figure 5.5D and Supplemental Figure 
6.4C). Entry inhibition was measured for seven second-generation proteins (Figure 5.5E). Despite 
substantial differences in their sequences, all evaluated proteins potently inhibit HIV entry (IC50 





5.6 Evolved proteins bind Enfuvirtide-resistant 5-helix and inhibit entry of Enfuvirtide-
resistant HIV. 
 Given the amino acid diversity of the evolved helix, we reasoned that (at least some of) the 
evolved proteins recognize 5-helix (and thus gp41) in slightly different ways, or potentially with 
Figure 5.5 (A) Yeast display data from three rounds of generation 2 screening. (B) Sequence 
logo for residues of 20 unique proteins optimized during generation 2 of yeast display 
screening. (C) In vitro ELISA data of generation 2 variants relative to Sac7d-Cpep signal. 
Dashed line represents 100% cutoff for variants progressing through further analysis. (D) 
Protein expression of generation 2 evolved proteins in E. coli relative to Sac7d-Cpep.Dashed 
line represents cutoff for proteins progressing through further analysis. (E) Inhibition of HIV 
entry of Sac7d-Cpep, C-peptide, Enfuvirtude, and generation 1 optimized proteins. Error bars 
represent the standard error of the mean (SEM) for three separate experiments. If error bars 
are not visible, error is smaller than the data point. 
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different contributions to the binding energy at each evolved position. Given this, we rationalized 
that some of these evolved proteins could, in principle, inhibit mutated HIV-1 that is resistant to 
Enfuvirtide.  
 Enfuvirtide is given to patients as a last resort therapy due to in vivo degradation and 
recycling as well as rapid resistance from the virus against the peptide.[11] In patient studies, a 
frequent mutation to the gp41 NHR region that bestows Enfuvirtide resistance is V38A[10], 
however double substitutions have also been found that confer cross-resistance to Enfuvirtide and 
C-peptide (V38A/N42D).[26] With this in mind, we generated Enfuvirtide-resistant HIV IIIB 
virions with either the V38A single substitution (Figure 5.6A) or V38A/N42D double substitution 
(Figure 5.6B) to examine the efficacy of the evolved proteins in cocktail therapy. As in the live 
virus assay of the wildtype virus, HIV IIIB V38A or HIV IIIB V38A/N42D infection of CD4-
positive T cells is linked to GFP fluorescence and can be quantified using flow cytometry. 
 We envisaged that second generation proteins would have the greatest impact on inhibition 
of Enfuvirtide-resistant strains based on the location of the evolved residues to the substitutions on 
NHR in the binding interaction (Figure 5.6A and B, generation 2). All the second-generation helix-
grafted proteins exhibited potent inhibition of the Enfuvirtide-resistant double mutant strain 
compared to Enfuvirtide with IC50 values ranging from 4.3 nM to 83.7 nM which is better than 
Cpeptide for some mutants and comparable to the efficacy of Cpeptide for other versions (IC50 
~72.9 nM) (Figure 5.6C, and Table 5.7). A similar trend was seen for the single mutant strain 
(Figure 5.6D, and Table 5.7). Interestingly, Sac7d-Cpep and Sac7d-Cpep1.1 also retained 
inhibitory potency against both strains with IC50 values remaining relatively unchanged from 
wildtype HIV IIIB to HIV IIIB V38A/N42D despite the 73-fold change of C-peptide potency and 
573-fold change of Enfuvirtide potency against the double substituted virus (Figure 5.6C and D 
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and Table 5.7, entries 1 and 6). The binding contribution from the helix-grafted Sac7d-Cpep that 
allows it to retain affinity despite the identical binding interface to C-peptide could be attributed 
to the stability of the tertiary complex for helical formation and the contribution from the native 
residues surrounding the grafted mutations on the solvent-exposed helix.  
 The diversity of amino acid sequence along the evolved helix has shown to recognize and 
inhibit membrane fusion of three HIV-1 strains to varying degrees. A mixture of these C-peptide 
mimics could be reasoned to inhibit wildtype HIV-1 and prevent rapid resistance with their 
polyclonal nature. To make these protein therapeutics rival mAb therapies the in vivo stability 
needs to be addressed. 
 
Figure 5.6 (A) Position of V38A single mutation within the N-heptad repeat (tan) of gp41 that 
confers Enfuvirtide resistance and (B) position of V38A and N42D double mutations within the 
N-heptad repeat (brown) of gp41 that confers Enfuvirtide resistance and Cpeptide sensitivity. 
Mutations are highlighted in red. C-peptide is highlighted in density blue; regions evolved 
generationally are shown. (C) Inhibition of V38A and (D) V38A/N42D HIV entry. Error bars 
represent the standard error of the mean (SEM) for three separate experiments. If error bars 
are not visible, error is smaller than the data point. 
110 
 
5.7 Fusions designed for serum stability potently inhibit HIV entry. 
 Small proteins like Sac7d-Cpep, and variations thereof, are typically cleared rapidly from 
the body[27, 28], compared to antibodies (e.g., IgG), which have much longer lifetimes in vivo 
(ca. half-life is approximately 22 days). This incredible stability in vivo is largely due to an 
interaction between the neonatal receptor (FcRn) on the surface of epithelial cells, and an epitope 
largely within the CH3 domain of a single chain of the fragment crystallizable region (Fc) (Figure 
5.7A).[29, 30] This single chain is referred to as monomeric Fc (mFc, Figure 5.7A); a single CH3 
domain is referred to as monomeric CH3 (mCH3, Figure 5.7A). Binding between mFc and FcRn 
is pH-dependent. Formation of the Fc/FcRn complex leads to a complicated process that 
continuously shuttles the antibody from the circulatory system to the cell interior. Once inside an 
endosome, which has a lower pH compared to the cytosol, the complex dissociates and the 
antibody is shipped back to the circulatory system.[29-31] This biological shell game allows 
antibodies to evade cellular degradation. Researchers have shown that fusion of a protein to mFc, 
or mCH3 can dramatically improve in vivo stability, and mFc or mCH3 fusions can often be 
expressed in E. coli.  
 We prepared two fusions, mFc-Sac7d-Cpep and mCH3-Sac7d-Cpep (Figure 5.7B). Given 
that Sac7d binds IgG, all protein fusions had an L33T mutation to turn ‘off’ affinity for IgG.[22] 
In vitro ELISA experiments indicate no appreciable binding between Sac7d L33T and either mFc 
or mCH3 (Supplemental Figure 6.4D). mCH3-Sac7d-Cpep (24 kDa) compares favorably to Sac7d-
Cpep, but the increased size results in a 1.5-fold decrease in entry inhibition (IC50 ~18.0 nM, Figure 
5.7C and Table 5.7, entry 22). Consistent with previously observed relationships between protein 
size and entry inhibition potency, mFc-Sac7d-Cpep (37 kDa) retains modest inhibition of HIV 
entry (IC50 ~282.9 nM, Figure 5.7D and Table 5.7, entry 20), but is approximately 23-fold less 
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potent than Sac7d-Cpep. Additionally, mCH3-Sac7d-Cpep and mFc-Sac7d-Cpep proteins 
containing a (GGS)3 linker between the mFc or mCH3 and Sac7d-Cpep performed similarly to 
proteins without a linker, despite the increase in size (Figure 5.7C and D and Table 5.7, entries 21 
and 23). 
 Fusion to a polypeptide that binds serum albumin has also been reported as a strategy to 
improve in vivo stability of biologics – presumably because binding to serum albumin effectively 
shields proteins from serum proteases and shuttles proteins through the FcRn pathway (Figure 
5.7A).[29, 31-33] We therefore prepared a fusion consisting of a 20-amino acid serum albumin 
binding peptide (SAbp) and Sac7d-Cpep (SAbp-Sac7d-Cpep, Figure 5.7B). Again, consistent with 
previously observed relationships between protein size and entry inhibition potency, SAbp-Sac7d-
Cpep (14 kDa, IC50 ~3.9 nM) compares identically to Sac7d-Cpep (12 kDa, IC50 ~1.9-12.4 nM)  
(Figure 5.7E and Table 5.7, entry 24). Additionally, since SAbp was a minimalist fusion, we tried 
fusing it to the C-terminus of Sac7d-Cpep. Concerned this would unfold the helix, we inserted a 
helix-forming linker between Sac7d-Cpep and SAbp.[33] This fusion protein (Sac7d-Cpep-hfl-
SAbp) showed similar inhibition (IC50 ~9.7 nM, Figure 5.7E and Table 5.7, entry 25).  
 Collectively, we report a new helix-grafted display biologic, Sac7d-Cpep, that potently 
inhibits the entry of HIV-1 in CD4-positive mammalian cells (IC50 ~1.9-12.4 nM). Yeast display 
evolution of native and grafted amino acids on the solvent-exposed helix face led to the generation 
of a cocktail of HIV-1 entry inhibitors with virtually identical potencies, despite significant 
sequence variation. While hydrophobic residues are principally selected for, the size of evolved 
residue side chains varies dramatically.  Importantly, evolved biologics potently inhibit the entry 
of mutated forms of HIV-1 containing Enfuvirtide-resistant changes in amino acid composition in 
gp41. Helix-grafted HIV-1 entry inhibitors fused to either mCH3, mFc, or SAbp, designed for 
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serum stability and long in vivo residence, retain the ability to inhibit HIV-1 entry; however, we 
do observe a correlation between the size of the fusion and potency – larger fusions generally have 
lower potency. However, all proteins reported here potently inhibit HIV-1 entry, including entry of 
Enfuvirtide-resistant HIV-1 (IC50 ~2.1-83.7 nM, Table 5.7). Given the amino acid diversity of 
evolved biologics we report, within the solvent-exposed helix face, we speculate that these 
biologics bind the C-peptide binding cleft of 5-helix somewhat differently, with varied energetic 
contributions at each evolved amino acid position. Thus, we also speculate that when used as a 
cocktail, it might be unlikely that HIV-1 is able to rapidly evolve resistance against the entire 
therapeutic cocktail. 
 
Figure 5.7 (A) Crystal structure of the FcRn receptor (grey) bound to both mFc (light pink) and 
Serum Albumin (light blue) (B) Fusion protein candidates (mFc ~21 kDa, mCH3 ~12kDa, SAbp 
~2kDa) to elongate in vivo stability. (C) Inhibition data of fusion protein mCH3-Sac7d-Cpep, 
(D) mFc-Sac7d-Cpep, or (E) SAbp-Sac7d-Cpep with and without linkers. Error bars represent 
the standard error of the mean (SEM) for three separate experiments. If error bars are not 





 5.8 Conclusion 
 HIV/AIDS afflicts 36.7 million people worldwide, and currently there is no vaccine or 
cure. Current HIV drugs target many facets of the virus lifecycle; however, entry inhibitors are 
limited and come with their own challenges. Moreover, most current HIV drugs require daily 
administration. Here, we set out to develop gp41 C-peptide helix-grafted proteins that potently 
bind gp41, inhibit HIV entry, and are designed to have in vivo stabilities that compare favorably to 
monoclonal antibodies. Expanding on our prior work using helix-grafted display, here we report 
Sac7d-Cpep, which potently inhibits HIV entry in a live virus assay (IC50 ~1.9-12.4 nM). Using 
yeast display, we resurfaced the solvent-exposed face of the grafted helix. This resulted in 
numerous new proteins with sequence-diverse grafted helices, which potently inhibit HIV entry. 
Given the sequence diversity of these helices, we speculated that these evolved proteins likely bind 
Table 5.7 Sequence of HIV entry inhibitor biologics and associated half-maximal inhibitory 
concentration (IC50) values for all live virus assays. Range represents cumulative data from all 
experiments of a given protein. Error represents the standard error of the mean (SEM) and the 
range of associated experiments.  
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gp41 slightly differently, and therefore might be effective against HIV strains that are resistant to 
Enfuvirtide, an FDA approved HIV entry inhibitor that binds prefusogenic gp41. Satisfyingly, we 
found that many of our evolved proteins inhibit entry of an HIV strain resistant to Enfuvirtide. 
Finally, we demonstrated that protein fusions consisting of the helix-grafted display entry inhibitor 
and polypeptides shown to increase in vivo stability express readily in E. coli, and in some cases, 
exhibit properties (recognition of the neonatal receptor) necessary for extended in vivo stability. 
Collectively, we report a virtual cocktail of HIV entry inhibitors that potently block HIV entry—
including in a strain resistant to Enfuvirtide—and demonstrate function necessary for long in vivo 
lifetime. Future work associated with this research would analyze the in vivo stability using animal 
models to produce a therapeutic with minimal immunogenic effect and maximal inhibitory 
effects.[23]  
 
 5.9 Methods 
Protein Expression and Purification  
Genes were cloned into pET using BamHI and KpnI, downstream of a His6 tag and transformed 
into BL21s (DE3). Cells were grown in 0.5 L LB cultures containing 100 μg/mL carbenicillin at 
37 °C to OD600 =0.5 - 0.8 and induced with 1 μM IPTG at 25 °C overnight. Cells were then 
collected by centrifugation, resuspended in PBS buffer (20 mM Na2HPO4 pH 7.4, 100 mM NaCl) 
with protease tablets and stored at -20 °C. Frozen pellets were thawed and sonicated with 1 sec 
pulses for 2 min. The lysate was cleared by centrifugation (11,899 xg, 10 min.) and the supernatant 
was mixed with 1 mL of Ni-NTA agarose resin for 30 min at 4 °C. The resin was collected by 
centrifugation (4,303 xg, 10 min.). The resin was sequentially washed with 30 mL of PBS buffer 
containing 20 mM imidazole, 50 mL PBS buffer containing 50 mM imidazole, and 15 mL PBS 
115 
 
buffer containing 75 mM imidazole. The protein was then eluted with 4 mL PBS buffer containing 
400 mM imidazole. The proteins were dialyzed against PBS buffer and analyzed for purity by 
SDS-PAGE. Purified protein concentrations were quantified using Beer’s Law at an absorbance 
of 280 nm, following standard practice. Protein expression was calculated as a measure of eluted 
protein yield in milligrams per liter of induced E. coli culture. Protein fusions with either mFc or 
mCH3 were grown up in 2XYTand induced at 20 °C for 15-20 hours for maximal yield.  
Circular Dichroism  
Proteins were purified as described above. Separately, each protein was diluted to 5-12 μM in PBS 
buffer. Wavelength data are the average of three scans from 250 nm to 200 nm in 1 nm steps at 25 
°C. Thermal denaturation experiments at 222 nm were run from 0 to 90 °C in two-degree steps at 
a two-degree/min rate of increase with one min equilibration and data averaging at each 
temperature. Tm values were obtained from minima of the first derivative of θ versus 1/T plots.  
Cell lysate ELISA  
Sac7d, Sac7d-Cpep, and C-peptide were cloned into MCS1 of pETDuet-1 with FLAG tags using 
NcoI and NotI. The 5-Helix with a C-terminal His6 tag was cloned into MCS2 of pETDuet-1 using 
NdeI and KpnI. For protein expression, constructs were transformed into BL21 cells (DE3). Cells 
containing the co-expressed pair were inoculated and induced in 10 mL LB cultures overnight. 
Cells were spun down and resuspended in 10 mL PBS buffer, lysed by sonication, and spun down 
to remove cell debris. Cleared lysates were incubated on clear Ni-NTA coated plates for 1 hr at 
room temperature and each well was washed 3x with 200 μL wash buffer (PBS Buffer, 0.1% 
Tween® 20, and 0.01 mg/mL BSA). An HRP-conjugated mouse anti-DDDDK antibody in LiCor 
Blocking Buffer was incubated for 1 hr at room temperature, followed by 3 washes. Color was 
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developed using TMB-One substrate and absorbance was measured at 655 nm on a SynergyMx 
Microplate Reader. 
Plasmid Construction of HIV-1 Infectivity Assays 
HIV-1 IIIB C200 proviral expression construct has been described previously. NheI/BamHI 
fragments of the env gene encoding substitutions (gp41 V38A or gp41 V38A N42D) were 
synthesized (INTEGRATED DNA TECHNOLOGIES), cloned into pJET1.2/blunt cloning vector 
(Thermo Scientific) by amplifying with the following primer set (5’-GCT AGC AAA TTA AGA 
GAA CAA TTT GG-3’ and 5’-GGA TCC GTT CAC TAA TCG AAT GG-3’) and sequenced as 
described previously. Then, DNA fragments were inserted into the proviral DNA expression 
plasmid at NheI/BamHI site. 
Infectivity Assay 
The procedure of HIV-1 infectivity assays was previously reported. Briefly, viruses were produced 
by transfection of 3.0 µg of HIV-1 IIIB C200 proviral expression construct into 293T cells 
(3.0x106) using TransIT®-LT1 reagent. 48h later, virus-containing supernatants were filtered by 
0.45 µm filters (Millipore) and used to infect into 2.5x104 CEM-GFP cells with varying 
concentration of inhibitors including T-20 and C34. Infectivity (GFP+ cells) was measured by flow 
cytometry at 2 days post-infection. 
Resolubilization of 5-helix Inclusion Bodies  
5-helix-His6 was cloned into a modified pETDuet-1 vector using NdeI and KpnI and transformed 
into BL21 cells. Cells were induced to express 5-helix-His6 and lysed as described above. The 
lysate was cleared by centrifugation (11,899 x g, 20 min) and the supernatant was discarded. The 
pellet was washed twice with PBS buffer containing 0.5 % Triton® X-100 and once with PBS 
buffer, resuspended in urea buffer (PBS buffer with 8 M urea and 10 mM imidazole) to resolubilize 
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the inclusion bodies and cleared by centrifugation (11,899 xg, 30 min.) The supernatant was mixed 
with 1 mL of Ni-NTA agarose resin for 1 hr at 4 °C. After centrifugation (4,303 x g, 4 min), the 
resin was washed with 50 mL of urea buffer and eluted with 40 mL of urea elution buffer (PBS 
buffer with 6 M urea and 100 mM imidazole) into 460 mL PBS buffer by gravity elution while 
stirring to refold the protein. The 500 mL elution was run through a column containing 1 mL of 
Ni-NTA agarose resin and eluted with 5 mL PBS buffer containing 400 mM imidazole. The protein 
was dialyzed against PBS buffer and analyzed for purity by SDS-PAGE. Refolding analysis was 
conducted by CD. Purified proteins were quantified using Beer’s Law at an absorbance of 280 nm. 
Protein expression was calculated as a measure of eluted protein yield in milligrams per liter of 
induced E. coli culture. 
Biotinylation 
5-helix-His6 was cloned into a pET vector containing an upstream Avitag™ 
(GLNDIFEAQKIEWHE)-GGSGGSGGT linker using KpnI and PacI. The protein was 
resolubilized from inclusion bodies as described above in PBS. His6-BirA was cloned into pET 
using NcoI and KpnI and purified as described above in PBS. 300 L of Avitagged™ 5-Helix-
His6 protein at 38 μM was incubated with 6 μL of His6-BirA at 1 mg/mL using Avidity® BirA 
biotin-protein ligase standard reaction kit at 30°C for 40 min. Biotinylation was confirmed by 
Agilent 6220 TOF LC-MS.  
In vitro ELISA 
Sac7d and helix-grafted Sac7d-Cpep were cloned into a pET vector downstream of an N-terminal 
His6-FLAG tag (DYKDDDDK) using BamHI and Kpn1 or BamHI and PacI. Proteins were 
purified as described above in PBS buffer. The biotinylated Avi-tagged 5-helix-His6 (biotin-5-
helix) was prepared as described above in PBS buffer and diluted to 10 μg/mL. Pierce® 
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Streptavidin coated clear 96-well plates with a binding capacity of 5 pmol were pre-blocked with 
200 μL of wash buffer (PBS, 0.5 mg/mL BSA, 0.1% tween® 20) for 1 hr. Biotin-5-helix was 
immobilized on the streptavidin-coated plates by incubating 100 μL of diluted protein for 1 hr at 
room temperature, followed by 3 washes. 100 μL of Sac7d or Sac7d-Cpep was incubated in various 
concentrations for 1 hr and washed 3 times at 4°C (All concentrations of incubated helix-grafted 
protein were above ligand-depleting conditions for binding the 5 pmol immobilized biotin-5-helix 
in each well). An HRP-conjugated mouse anti-DDDDK antibody in LICOR Blocking Buffer 
(1:10,000) was incubated for 1 hr at room temperature, followed by 4 washes at 4°C. Color was 
developed using TMB-One substrate at room temperature and absorbance was measured at 655 
nm on a SynergyMx Microplate Reader after 20 min.  
Preparation of Protein Library Generation 1  
EBY100 yeast (trp-, leu-, with the Aga1p gene stably integrated) and the pCTCON2 plasmid were 
generously provided by the Wittrup lab (MIT). The gene encoding Sac7d-Cpep was amplified by 
PCR and cloned into pCTCON2 in-frame with Aga2, an N-terminal HA-tag, and an N-terminal 
myc tag, using the restriction enzymes NheI and XhoI. When analyzed for display only, Sac7d-
Cpep displayed efficiently on EBY100 cells (~60-85 %, data not shown). Next, the Sac7d-Cpep 
generation 1 library was created by amplifying the N-terminal Sac7d-Cpep gene with an N-
terminal homologous recombination forward primer annealing to 40 base pairs upstream of the 
gene on pCTCON2 and a reverse homologous recombination primer containing 5 sites in the C-
terminal α-helical region (Glu65, Ile66, Tyr69, Thr70, and Ile73) substituted with NNK codons 
and annealing to 40 base pairs downstream of the final NNK mutation. The resulting amplicon, 
containing the randomized sequences, was then cloned into a nonsense-Cpep pCTcon2 vector 
containing the remainder of the C-terminus of Sac7d-Cpep post-mutations by adding ~1 µg of 
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nonsense-Cpep pCTCON2 vector cut with NheI and NcoI mixed with ~3 µg of the amplified 
library, ethanol precipitated, and transformed via homologous recombination into 
electrocompetent EBY100. Eight of these electroporations were performed to reach appropriate 
transformation efficiency. Rescued yeast were resuspended in 1 mL fresh SD-CAA (5.4 g/L 
Na2HPO4, 8.6 g/L NaH2PO4 • H2O, 20 g/L dextrose, 6.7 g/L yeast nitrogen base lacking amino 
acids, 5 g/L casamino acids, 200 kU/L penicillin, 0.1 g/L streptomycin). A small portion was plated 
by serial dilution onto SD-CAA plates, and incubated at 30 °C for 3 days in order to determine the 
transformation efficiency. The remainder were cultured in 50 mL SD-CAA for yeast display 
screening. Efficiency of homologous recombination transformation was determined to be 1.072 x 
107 – 2.19 x 107 using the equation transformation efficiency = (# colonies x Vol 
quenched)/(dilution x Vol plated). 
Preparation of Protein Library Generation 2 
The gene encoding the best performing mutant from generation 1, Sac7d-Cpep1.1 pCTCON2 was 
electroporated back into pCTCON2 in-frame with Aga2, an N-terminal HA-tag, and an N-terminal 
myc tag, using NheI and XhoI. When analyzed for display only, Sac7d-Cpep1.1 displayed 
efficiently on EBY100 cells (~60-85 %, data not shown). Next, the Sac7d-Cpep generation 2 
library was created by amplifying the N-terminal Sac7d-Cpep1.1 gene with an N-terminal 
homologous recombination forward primer annealing to 40 base pairs upstream of the gene on 
pCTCON2 and a reverse homologous recombination primer containing 5 sites in the C-terminal 
α-helical region (Leu76, Ile77, Ser80, Gln83, and Gln84) substituted with NNK codons and 
annealing to 40 base pairs downstream of the final NNK mutation. The resulting amplicon, 
containing the randomized sequences, was then cloned into a nonsense-Cpep2 pCTCON2 vector 
containing the remainder of the C-terminus of Sac7d-Cpep1.1 post-generation 2 mutations using 
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homologous recombination in EBY100 yeast by using approximately 1 µg of nonsense-Cpep2 
pCTCON2 vector cut with NheI and PacI mixed with ~3 µg of the amplified generation 2 library, 
ethanol precipitated, and transformed via ten electroporations. Rescued yeast plated as described 
previously to determine the transformation efficiency and the remainder were cultured in 50 mL 
SD-CAA for yeast display screening. Efficiency of homologous recombination transformation was 
determined to be 2.084 x 107 – 4.9 x 107. 
Yeast Display Screening 
After 2-3 days of growth in SD-CAA, the library was sub-cultured in SD-CAA at an initial density 
of 0.5 x 107 cells/mL and grown to a density of 2.0 x 107 cells/mL. Yeast were subsequently sub-
cultured in SG-CAA (Galactose containing induction media) to a concentration of 1.0 x 107 
cells/mL and grown for 1-2 days shaking at 250 rpm at 25 °C. For each round of screening, 
approximately 108 cells were pelleted and washed with 1 mL of 4 °C PBS-BSA (PBS buffer with 
1 g/L BSA filter sterilized). Yeast were subsequently incubated with biotin-5-helix at the 
concentrations given in Supplemental Table 6.4 and a fluorescein isothiocyanate (FITC)-
conjugated anti-myc antibody (1:250) at room temperature. After incubation, the yeast cells were 
incubated on ice for 5 min, pelleted at 12,000 xg for 30 sec 4 °C and washed with 1 mL ice-cold 
PBS-BSA. The yeast were pelleted again and incubated with a 1:100 dilution of streptavidin, R-
Phycoerythrin (SA-PE) in PBS-BSA on ice for 1 hr. After incubation, a final wash with ice-cold 
PBS-BSA was performed, and yeast positive for both FITC (display) and R-Phycoerythrin (PE, 5-
helix-binding) were sorted into 7 mL of SD-CAA media using a MoFlo Flow Cytometer 
(Beckman-Coulter). Sorted yeast were transferred to 50 mL of pre-warmed SD-CAA and 
incubated at 30 °C for 3 days shaking at 250 rpm. Additionally, plasmid DNA from the sorted 
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library population was recovered using a Zymoprep yeast plasmid miniprep II kit. This DNA was 
used to transform Invitrogen, Top10 E. coli and analyzed for sequence diversity.  
Viral Infectivity Assays for IC50 Determination 
The yield of infected cells produced was quantified by flow cytometry and normalized relative to 
maximum dosages. The concentrations that caused 50% inhibition (IC50) were calculated using the 
nonlinear fit variable slope model where n=3 (Prism, GraphPad Software). Error in IC50 values 
were determined for each concentration using standard deviation and each concentration was 
evaluated for significance by T-test.  
Statistical Analysis 
Statistical tests and the associated standard deviation error bars are identified in the figure captions. 
Statistical analysis was performed using Prism (GraphPad Software). 
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Supplemental Figure 6.1 (A) Mass spectrometry of Avi-tagged 5-helix-his and biotinylated 
avi-5-helix-his shows 100% biotin conjugation. (B) Nickel pulldown of E. coli cell lysate 
expressing 5-helix-his and untagged GLUE-Cpep in a 1:1 ratio (densitometry data not shown). 
(C) Mass spectrometry of E. coli cell lysate expressing 5-helix-his and untagged GLUE-Cpep 
after Nickel NTA purification. Untagged GLUE-Cpep is copurified with 5-helix-his indicating 
binding in complex cellular milieu.  
134 
 









Supplemental Figure 6.2 (A) Protein expression of native scaffold candidates through Ni-
NTA column purification and analysis via SDS-PAGE. (B) Mass spectrometry data of 
biotinylation reaction displaying 100% conjugation from Avi-tagged 5-helix-his (left, 27,694 Da) 
to biotin-5-helix-his (right, 27,920 Da).  
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Supplemental Figure 6.3 A) Mass spectrometry of Avi-tagged 5-helix-his (left) and 
biotinylated avi-5-helix-his (right) shows 100% biotin conjugation to protein. (B) SDS-PAGE 
confirmation of Cpep-ELMO and Cpep-ELMO mutants used in this work (Cpep1-ELMO, 
Cpep3-ELMO, Cpep4-ELMO, Cpep5-ELMO, and Cpep8-ELMO).  
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Supplemental Figure 5.11 (A) SDS-PAGE gel displaying protein expression and purity of 
Sac7d scaffold (lane 1) and helix-grafted Sac7d-Cpep (lane 2). (B) SDS-PAGE gel displaying 
protein expression of FLAG-tagged Sac7d-Cpep and generational variants. (C) In vitro ELISA 
of binding interaction between Sac7d and either mCH3 or mFC. Sac7d L33T mutation reduces 
ELISA signal (orange bar) thus turning off binding to mFc. Error bars represent the standard 
error of the mean (SEM) for three separate experiments. If error bars are not visible, error is 
smaller than the data point. 
Supplemental Table 5.11 Library screening schematic for all 5 rounds of cell sorting.  
